Document:

EX-10.24

 EXHIBIT 10.24 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
 Dated:
8 October 2013         
 OXFORD IMMUNOTEC LIMITED 

and 
 SHANGHAI FOSUN LONG MARCH
MEDICAL 
 SCIENCE CO. LTD. 
 and

 SHANGHAI XIN CHANG MEDICAL DEVICE CO. LTD. 
  

 
 DISTRIBUTORSHIP
AGREEMENT 
  
  

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL 

TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS 

BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 

 

							
	
	 CONTENTS
	   

		
	 OXFORD IMMUNOTEC LIMITED
	  	 	1	  
		
	 SHANGHAI FOSUN LONG MARCH MEDICAL SCIENCE CO. LTD.
	  	 	1	  
		
	 SHANGHAI XIN CHANG MEDICAL DEVICE CO. LTD.
	  	 	1	  
		
	 DISTRIBUTORSHIP AGREEMENT
	  	 	1	  
			
	 1
	 	 DEFINITIONS AND INTERPRETATION
	  	 	3	  
			
	 2
	 	 APPOINTMENT
	  	 	6	  
			
	 3
	 	 DISTRIBUTOR’S DUTIES
	  	 	6	  
			
	 4
	 	 FORECASTS AND ORDERS
	  	 	11	  
			
	 5
	 	 CHANGES TO THE PRODUCTS AND NEW PRODUCTS
	  	 	12	  
			
	 6
	 	 PRICES AND PAYMENT
	  	 	13	  
			
	 7
	 	 THE COMPANY’S DUTIES
	  	 	14	  
			
	 8
	 	 LIMITATION OF LIABILITY
	  	 	16	  
			
	 9
	 	 CONFIDENTIALITY
	  	 	16	  
			
	 10
	 	 INTELLECTUAL PROPERTY
	  	 	17	  
			
	 11
	 	 PRODUCT LIABILITY AND INSURANCE
	  	 	18	  
			
	 12
	 	 TERM AND TERMINATION
	  	 	19	  
			
	 13
	 	 CONSEQUENCES OF TERMINATION OR EXPIRY
	  	 	21	  
			
	 14
	 	 SUPERVENING LAWS AND FORCE MAJEURE
	  	 	23	  
			
	 15
	 	 ASSIGNMENT
	  	 	23	  
			
	 16
	 	 MISCELLANEOUS
	  	 	24	  
			
	 17
	 	 NOTICES
	  	 	24	  
			
	 18    
	 	 LANGUAGE AND LAW; DISPUTE RESOLUTION
	  	 	24	  

  
 - 2 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 This Agreement is made on the 8th Day of October 2013

 Between 
 Oxford Immunotec Limited (registered number
4516079) whose registered office and principal place of business is at 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RY, UK (“the Company”), Shanghai Fosun Long March Medical Science Co. Ltd. 

 (“Fosun Shanghai I”) (registered number Shanghai Joint-Venture 000422) whose registered office and principal place of business is both at 830 Cheng Yin Road, Shanghai, China, 200444 and Shanghai Xin Chang
Medical Device Co. Ltd.(

)(“Fosun Shanghai II”) (registration number 310110000477786) whose registered office is at 830 Cheng Yin Road, Shanghai, China, 2004444, (Fosun Shanghai I, Fosun Shanghai II jointly referred to as the
“Distributors” and individually as the “Distributor”), together the parties (“the Parties”). 
 Whereas: 

 

	 	A.	The Company is engaged in the business of developing, producing, marketing and selling diagnostic systems; 

  

	 	B.	The Company obtained PRC Registration on or about 24 August 2010 for its T.SPOT®-TB test and 14 May 2013 for its T-CELL Xtend reagent and,
by a Registration Agreement (as define below), has appointed Fosun Shanghai I as its attorney with a view to obtaining renewal of the PRC Registration as directed by Company; 

 

	 	C.	The Company wishes to appoint the Distributors to distribute tuberculosis diagnostic systems in the Territory (as defined below) upon the following terms and conditions; and 

 

	 	D.	The Distributors wish to distribute such tuberculosis diagnostic systems in the Territory and the Company is agreeable to the Distributors doing so upon the following terms and conditions. 

IT IS AGREED as follows: 
  

	1	DEFINITIONS AND INTERPRETATION 

  

	 	1.1.	In this Agreement the following words and phrases shall have the following meanings unless the context requires otherwise: 

  

	 	1.1.1.	“Agreement” shall mean this document, together with its schedules; 

  

	 	1.1.2.	“Business Day” shall mean any day of the week other than Saturday, Sunday, a bank or public holiday in England or a public holiday in China; 

 

	 	1.1.3.	“Consumables” shall mean the accessories listed in Schedule 3 and such other accessories of the Company of which the Company may notify the Distributor in writing from time to time; 

 

	 	1.1.4.	“Contract Year” shall mean the calendar year commencing January 1 of the Term; 

  
 - 3 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	1.1.5.	“Distributor Affiliate” shall mean (i) any corporation or business entity of which the Distributor (meaning either individual Distributor named herein) has either (a) thirty (30%) or more of the
ownership of the corporation or business entity or (b) thirty (30%) or more of the power to vote on or direct the affairs of the corporation or business entity and (ii) any individual who has either (a) thirty (30%) percent
or more of the ownership of a Distributor or a Distributor Affiliate or (b) thirty (30%) percent or more of the power to vote on or direct the affairs of a Distributor or a Distributor Affiliate; 

 

	 	1.1.6.	“Effective Date” shall mean 1 January 2014. 

  

	 	1.1.7.	“Kits” shall mean kits of T-SPOT®.TB in vitro diagnostic assays for the detection of mycobacterium tuberculosis infection in humans (and the associated reagents), as described in the Specification,
and any Replacement Kits from time to time; 

  

	 	1.1.8.	“Improved Kits” shall mean any new version of the Kits (that are not Replacement Kits, as defined below) developed by the Company which the Company markets and sells and which are improvements on the Kits;

  

	 	1.1.9.	“Intellectual Property Rights” shall mean any patent, trademark, service mark, registered design, copyright, design right, database right, rights protecting confidential information, any applications for or
rights to apply for or to be granted any of the above and any other intellectual property right recognised in any part of the world, whether or not now existing or applied for, and all accrued rights of action in respect of any such rights;

  

	 	1.1.10.	“Minimum Quantities” shall mean the minimum number of Kits that must be purchased by the Distributor for delivery in each Year, as specified in Schedule 2; 

 

	 	1.1.11.	“New Consumables” shall mean any new, additional or substitute version of the accessories listed in Schedule 3 which the Company chooses to market in the Territory for use with the Kits, Improved Kits or
Replacement Kits; 

  

	 	1.1.12.	“New Products” shall mean product that is complementary to the Kits that the Company may develop and choose to market in the Territory during the Term of this Agreement; 

 

	 	1.1.13.	“OI Accessories” shall mean T-CELL Xtend® and Leucosep tubes; 

  

	 	1.1.14.	“Other Products” shall mean the Consumables, Improved Kits, and Replacement Kits; 

  

	 	1.1.15.	“Price” shall mean the price of the Products payable by the Distributor to the Company as set out in the schedules, as amended from time to time by Company in accordance with Section 6.1;

  
 - 4 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	1.1.16.	“Products” shall mean the Consumables, Kits, Improved Kits, OI Accessories, and Replacement Kits; 

  

	 	1.1.17.	“Registration” shall mean, with respect to marketing of and sales of the Kits (excluding Replacement Kits) in China, the approval of and/or re-registration with PRC China Food and Drug Administration
(“CFDA”)to market the same in China (the “PRC Registration”), with respect to marketing of and sales of any Replacement Kits, the updated approval of and registration with PRC State Food and Drug Administration to market the same
in China, as applicable (the “Replacement PRC Registration”), and with respect to marketing of and sale of the Kits in Hong Kong and Macau, as applicable the approval of and registration with the Pharmaceutical Service of the Department of
Health to market the Kits in Hong Kong, and the approval of and registration with the Macau Department of Health to market the Kits in Macau, respectively, all in the name of the Company; 

 

	 	1.1.18.	“Registration Agreement” shall mean the agreements dated 5 June 2009 and 14 November 2011, as amended, by and between Fosun Shanghai II and Company relating to Registration of Products and T-Cell
Xtend; 

  

	 	1.1.19.	“Replacement Kits” shall mean any diagnostic products which the Company designates as a new product superseding and replacing the Kits in the Company’s product line; 

 

	 	1.1.20.	“Specification” shall mean the specification of the Kits and OI Accessories as set out in Schedule 4 and amended from time to time; 

 

	 	1.1.21.	“Technology” shall mean all technical information (i) owned by or licensed to the Company and existing at the Commencement Date or (ii) originated or acquired by the Company during the Term of this
Agreement relating to the Kits, Improved Kits, New Products, and/or Replacement Kits which is of a secret or confidential nature; 

  

	 	1.1.22.	“Term” shall mean a period starting on the Effective Date and ending on the seventh anniversary of the Effective Date; 

  

	 	1.1.23.	“Territory” shall mean the People’s Republic of China (“PRC”), which, for the avoidance of doubt, shall include Hong Kong and Macau Special Administrative Regions, but for the purposes of this
Agreement shall exclude Taiwan; and 

  

	 	1.1.24.	“Trademarks” shall mean the marks identified in Schedule 5 and such other marks as the Company notifies the Distributor in writing that it may use under this Agreement and. 

 

	 	1.2.	The headings to the clauses in this Agreement are for convenience and shall not affect the construction of the Agreement. 

  
 - 5 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	IA	CONDITIONS PRECEDENT AND EFFECTIVENESS OF THIS AGREEMENT 

  

	1A.1	Each of the Distributors hereby represents and warrants that (i) it has obtained and, if requested by the Company, provided the Company with true and complete copies of all approvals including PRC regulatory
authorizations that are required for its entry into this Agreement and performance of its obligations hereunder; and (ii) the execution, performance and compliance by it with the terms of this Agreement, and the consummation of the transactions
contemplated herein, do not and will not result in any violation, breach or default, or be in conflict with or constitute, with or without the passage of time or the giving of notice or both, either (a) a default under such Distributor’s
charter documents or any contract, agreement or instrument to which such Distributor is a party or to which the assets or any portion thereof of such Distributor is subject, (b) an event which results in the creation of any lien, charge or
encumbrance upon any assets of such Distributor, or (c) any violation of applicable law. 

  

	1A.2	The Distributor shall, and shall procure that the Distributor Affiliates shall, use best efforts to obtain renewal of the PRC Registration in accordance with Registration Agreement and applicable law. 

 

	1A.3	Beginning on the Effective Date, this Agreement shall supersede and replace in its entirety that Distribution Agreement dated 5 June 2009. Prior to the Effective Date, the Distribution Agreement dated 5 June
2009 shall remain in full force and effect. Notwithstanding the foregoing, this Agreement shall not become effective and shall be null and void if the Convertible Promissory Note by and between the Company and Fosun Industrial Co., Limited dated
8 October 2013 is not funded by the Effective Date. 

  

	2	APPOINTMENT 

  

	 	2.1.	Subject to the terms and conditions set out herein, the Company hereby appoints the Distributors jointly as its exclusive distributor of the Kits and Improved Kits to the human diagnostic market in the Territory, except
that the appointment in Hong Kong Special Administrative Region shall be non-exclusive. 

  

	 	2.2.	Save as expressly set out in the Registration Agreement, neither Distributor shall represent itself as an agent of the Company for any purpose nor pledge the Company’s credit or give any condition or warranty or
make any representation on the Company’s behalf or commit the Company in any respect to any contracts or other obligations of any kind. Further, neither Distributor shall without the Company’s prior written consent make any promises or
guarantees with reference to the Products beyond those contained in the promotional material supplied by the Company or otherwise incur any liability on behalf of the Company. 

 

	3	DISTRIBUTOR’S DUTIES 

  

	 	3.1.	Subject to the applicable statutory requirements, each of the Distributors undertakes and agrees with the Company that it will at all times while this Agreement is in force observe and perform the terms and conditions
of this Agreement and in particular will: 

  

	 	3.1.1.	use its best endeavours to actively introduce, promote, sell and support the Kits, OI Accessories, and, as applicable, Other Products on a continuing basis in the entire Territory, including the arrangement of the terms
of sale, including price of the Products, between itself and its customers and delivery of Products to Distributors’ customers; additionally, the Distributor shall work with key opinion leaders in the Territory and conduct such clinical trials
as are appropriate; 

  
 - 6 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	3.1.2.	not resell Kits, OI Accessories, or Other Products outside the Territory; 

  

	 	3.1.3.	not for the period of this Agreement and for a period of 12 months after its termination either by itself or its officers, employees, agents, subsidiary or associated companies be concerned in or interested in the use,
production, marketing, distribution, sale or other dealing in any goods in the Territory which are the same as or competitive with the Kits or Other Products, except where the Distributor is selling the competitive products used for the diagnosis of
tuberculosis diagnostic in humans prior to the Commencement Date, as expressly agreed by the Company and the Distributor; 

  

	 	3.1.4.	not undertake commercialization or manufacturing activities of any kind in relation to the Kits, OI Accessories or Other Products, other than as expressly permitted under this Agreement; 

 

	 	3.1.5.	allow the Company or its duly authorized agent full access to inspect the Products from time to time and if the Company reasonably deems any of the Products to have become not saleable as a result of any act or omission
by the Distributor, such Products shall be disposed of by the Distributor strictly in accordance with the Company’s instructions, and Distributor shall, to the extent it has not previously done so, pay the Company the customer list price for
each such Product; 

  

	 	3.1.6.	provide quarterly status reports as to the progress of the Registration application; 

  

	 	3.1.7.	will not make any promises or guarantees with reference to the Kits, OI Accessories or any other Product other than (i) as set forth in the Company’s Conditions of Sale, as they may be amended by the Company
from time to time (the current version of which is attached hereto as Schedule 4) and (ii) in Hong Kong where the Distributor may refer to the Kits CE mark and, when received and only when received, indicate that the PRC Registration has been
duly granted by the PRC State Food and Drug Administration; and for the avoidance of doubt shall not promote the Kits or OI Accessories for veterinary use; 

  

	 	3.1.8.	sell the Kits and OI Accessories on the condition that customers use the Kits and OI Accessories for human diagnostics only and without splitting up and selling separately the contents of any of the Kits or OI
Accessories and diligently take any action reasonably required by the Company (including without limitation, by applying specific labels or notices to Kits or OI Accessories and/or their packaging) to ensure that customers fulfill these conditions;

  
 - 7 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	3.1.9.	as required by the Company, submit written reports to the Company as at 31 March, 30 June, 30 September and 31 December of each year to be received by the Company within 10 working days after the due
date showing details of sales by region, service stock, outstanding customer orders and orders placed by the Distributor with the Company still outstanding, changes to the forecast and any other information relating to the performance of its
obligations under this Agreement that the Company may reasonably require from time to time. 

  

	 	3.1.10.	maintain on its own account an inventory of the Kits, OI Accessories, and Consumables at levels which are appropriate and adequate for the Distributor to meet all reasonable customer delivery requirements throughout the
Territory; 

  

	 	3.1.11.	keep full and proper books of account and records showing clearly all enquiries, quotations, transactions and proceedings relating to the Kits, OI Accessories, and Other Products; 

 

	 	3.1.12.	allow the Company, upon reasonable notice, access to its accounts and records relating to the Kits, OI Accessories, the stock of each and Other Products for the purpose of inspection; 

 

	 	3.1.13.	insure at its own cost with a reputable insurance company all stocks of the Kits, OI Accessories, and Other Products as are held by it against all risks which would normally be insured against by a prudent businessman
to at least their full replacement value; 

  

	 	3.1.14.	inform the Company immediately of any changes in ownership or control of the Distributor and of any change in its organisation or method of doing business which might affect the performance of the Distributor’s
duties under this Agreement; 

  

	 	3.1.15.	comply with all relevant regulatory requirements in connection with the Distributors’ activities under this Agreement, including without limitation those relating to importation, promotion, sales, licenses, product
recall, complaints, distribution and storage; not engage in any unfair trade practice, including, without limitation, (i) false or misleading representations concerning the Products, (ii) illegal “loss leader”, “bait and
switch” or other misleading or deceptive advertising or (iii) any practice designed improperly to control prices or (b) any conduct which could give rise to a violation of the UK Bribery Act, including, without limitation,
(i) the offering, giving, solicitation or acceptance of any bribe in order to gain any commercial, contractual, regulatory or personal advantage or (ii) making any payments to officials or public servants for securing or accelerating
routine processes and procedures (unless payment is for a recognised fast-track process available to all on payment of a fee); 

  

	 	3.1.16.	comply with all Applicable Laws in relation to its activities in relation to the Products including without limitation the UK Bribery Act 2010, in connection with its activities in relation to the Products;

  
 - 8 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	3.1.17.	immediately bring to the attention of the Company any improper or wrongful use of which the Distributor becomes aware of any patents or patent applications, registered designs, trademarks or trade names, including the
Trademarks, relating to the Kits, OI Accessories or any Other Product; 

  

	 	3.1.18.	comply with all reasonable advice of the Company relating to storage, safety precautions, security and maintenance of quality of the Kits and Other Products; 

 

	 	3.1.19.	maintain at its own expense trained personnel and storage facilities meeting the reasonable standards specified by the Company for the efficient storage, promotion and sale of the Kits, OI Accessories, and, as
applicable, Other Products throughout the Territory; 

  

	 	3.1.20.	to the extent it is using electronic or digital copies of marketing material relating to the Kits and OI Accessories supplied by the Company, as provided in Clause 7.1.4 hereof, use only the most current version of such
materials; at the request of the Company to discontinue use of marketing materials with content no longer approved for use by the Company; to submit Chinese and English language versions of all new advertising and promotional schemes and material
including copy and designs at an early stage as they relate to the marketing of the Kits, OI Accessories, and, as applicable, Other Products for the Company to comment upon and to arrive at a mutual agreement prior to publication or distribution;

  

	 	3.1.21.	keep the Company informed of the distribution of the Kits, OI Accessories, and, as applicable, Other Products in the Territory on a regular basis, at least once every quarter, or as reasonably directed by the Company
during the period of this Agreement and inform the Company of any information which it now has or which it may receive in the future which is likely to be of interest, benefit or use to the Company in relation to the marketing of the Kits, OI
Accessories, and, as applicable, Other Products in the Territory; 

  

	 	3.1.22.	provide the Company with Chinese language artwork for labels in compliance with the Registration and with all other applicable regulations to vials, plates and boxes; further, provide the Company with artwork for
Chinese language pack insert (which should be a complete and accurate translation of the English pack insert, amended to the necessary extent in order to comply with applicable PRC law) for the Company to insert to all Kits, OI Accessories, and, as
applicable, to accompany Other Products offered for sale by the Distributor; 

  

	 	3.1.23.	not act in any way which might prejudice the reputation of the Company or its Products; 

  

	 	3.1.24.	forward any customer complaint regarding the Kits, OI Accessories, or, as applicable, any Other Product to the Company within 3 Business Days of receipt. Such notification shall include the nature of the complaint, the
lot number of the batch affected, and the date when the complaint was first observed and as much other relevant data as can be gathered. The Distributor shall respond to the customer as directed by the Company; 

  
 - 9 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	3.1.25.	maintain appropriate up-to-date and accurate records to enable the immediate recall of any batches of the Kits, OI Accessories or any of them (or, as applicable, any Other Product) from any subsequent purchaser of the
Kits, OI Accessories or, as applicable, such Other Products. These records will include records of deliveries to customers (including details of lot and batch numbers, delivery date, name and address of customer, email address and telephone number
and fax or telex number if available); 

  

	 	3.1.26.	immediately comply with all reasonable instructions from the Company related to the recall of any of the Kits or OI Accessories (or, as applicable, any Other Products) or rectifying the Kits or OI Accessories (or, as
applicable, any Other Products) in the Territory; 

  

	 	3.1.27.	without the prior written consent of the Company, not delegate or sub-contract the performance of any of its obligations or assign any of its rights hereunder (but, for the avoidance of doubt and subject always to
clause 3.1.2, 3.1.8, 3.1.15, and 3.1.16 the Distributor may sell Kits and/or OI Accessories through agents or sub-distributors provided that, the Distributor shall (i) enter into an agreement with such agents and/or sub-distributors
respectively, which shall be consistent with the terms and conditions of this Agreement, including without limitation clauses 2.2, 3.1.2 to 3.1.28 (inclusive), (ii) remain liable for any breach by of any such agent or sub-distributor of any
obligation of a distributor under this Agreement and (iii) ensure that any agreement which the Distributor enters into with any agent or sub-distributor is co-terminus with this Agreement). The Company may waive the Distributor’s
obligations under this 3.1.26 on a case-by-case basis at its sole discretion; and 

  

	 	3.1.28.	not to reverse engineer or otherwise attempt to manufacture copies or variants of the Kits, OI Accessories or, as applicable, any Other Products, and not to manufacture, market, distribute or support any item that would
be competitive with the Kits, OI Accessories or any Other Products. 

  

	 	3.2.	Each Party hereby appoints the representative listed in this Clause 3.2 who shall have day-to-day responsibility for the management and performance of its obligations under this Agreement and for managing its
relationship with the other Party (for this purpose, the Distributors are treated collectively as a Party)(each a “Representative”). 

Representative of the Company: 

Peter Edwardson 
 General
Manager 
 Oxford Immunotec Ltd, 

94C Innovation Drive, Milton Park, 

Abingdon, Oxfordshire, 
 OX14
4RY, UK 

  
 - 10 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 Fax: +44 (0)1235 442781 

Representative of the Distributors: 

Joel Y Zhang 
 General Manager

 Shanghai Fosun Long March Medical Science Co. Ltd. 

830 Chengyin Road, Shanghai 200444, China 

Fax: 86-21-60765710 
 From time
to time during the term of this Agreement, either Party may change its Representative by written notice to the other Party of the details, including contact details, of its new Representative. 

The Parties shall procure that their respective Representatives shall regularly and, as frequently as deemed appropriate depending on market
and business circumstances, but no less than once every quarter, unless Oxford Immunotec expresses the need for monthly meetings (in which case such meetings shall be held monthly), such expression of need to be renewed every quarter, meet by
telephone to discuss the operation of this Agreement, or meet to discuss the same (if each Representative so agrees) in person. 
  

	4	FORECASTS AND ORDERS 

  

	 	4.1.	 No later than 30th November in each Contract Year (or such other date requested by the Company), the Distributors shall inform the Company in
writing of their forecast of the number of each type of the Product (for the avoidance of doubt for Kits, OI Accessories, Consumables, and, as applicable, New Products and Replacement Kits) which it expects to order from the Company for delivery
during the ensuing Contract Year (or such other date requested by the Company). The Distributor must inform the Company promptly if their forecasted requirements change as set out in 3.1.9. The Distributors will on or before the first day of each
Quarter give the Company a written rolling forecast of Distributors’ requirements for Products and Consumables for the next twelve months. The quantities identified for the first quarter of each such forecast shall be accompanied by
non-cancellable firm orders for such quantities and in the absence of accompanying firm orders, the forecast itself shall constitute a firm order of such quantities for that quarter; the quantities for the following nine months shall be a good faith
estimate of Distributors’ requirements for such period. No term included in any firm order that is in any way inconsistent with the terms and provisions of this Agreement, including without limitation the Conditions of Sale, shall have any
force or effect and the terms and provisions of this Agreement shall prevail. The Distributors shall collectively submit only one forecast for each quarter by the Distributors (and for avoidance of doubt, each Distributor shall not submit individual
forecasts). Likewise, any change of forecast under Clause 3.1.9 shall only be submitted collectively by the Distributors. Notwithstanding the 

  
 - 11 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	
foregoing, in the event the Company receives more than one forecast from the Distributors for any period, it may elect, in its sole discretion, to treat the multiple forecasts as an aggregate
firm order for the first quarter of the forecast and, in that event, the Distributors shall be liable to accept and pay for the aggregate quantity contained in the forecasts for such quarter. 

 

	 	4.2.	The Distributor shall submit all orders for Kits and Consumables in writing to the Company as set out in 4.1 above. 

  

	 	4.3.	Subject to clauses 3.1.9, 4.1 and 4.2, the Company undertakes to use reasonable endeavours to meet all firm orders for the Kits, OI Accessories, and Consumables placed by the Distributor in writing (including by fax) to
the extent that the orders do not exceed the original quarterly forecast for such quarter provided under clause 4.1 and the Distributor agrees to purchase the Kits, OI Accessories, and Consumables for its own account for resale pursuant to this
Agreement. In the event of a force majeure event, as further described in Clause 15.3 hereof, the Company may allocate to the Distributors an equitable portion of the Kits, OI Accessories, and, as applicable, the Other Products it has available for
delivery and the Distributors agree to accept such a reduced, equitable allocation under such circumstances. For the avoidance of doubt the Distributor may purchase Consumables locally subject to clause 4.5 of this agreement. 

 

	 	4.4.	The Distributors shall place orders with the Company in each Contract Year that meet or exceed the Minimum Quantities for that Contract Year. 

 

	 	4.5.	If Distributors do not order Consumables from the Company for use with Kits and/or New Products, they shall supply to their customers (for use with the Kits and/or New Products) only those substitute consumables which
the Company has validated for use with Kits and/or New Products (a list of which the Company will supply promptly after receiving a written request therefor). The Distributors shall be responsible for confirming the regulatory status of the
Consumables and substitute consumables in the Territory. 

  

	5	CHANGES TO THE PRODUCTS AND NEW PRODUCTS 

  

	 	5.1.	The Company may, upon giving one month’s written notice to the Distributors: 

  

	 	5.1.1.	exclude from this Agreement any Kits or OI Accessories that have been permanently discontinued; and 

  

	 	5.1.2.	make such changes as it deems fit to the Kits or the Product protocols subject to the regulatory requirements in the Territory. 

  

	 	5.2.	 If the Company (a) develops New Products and chooses to market and sell them in the Territory, and/or (b) markets and sells new accessories
which have utility with the Kits or OI Accessories, it shall not unreasonably refuse to agree to such items being included as Products under this Agreement, subject to reaching agreement in writing with

  
 - 12 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	
Distributors as to pricing and sales targets therefor and to satisfying any applicable regulatory approval requirements. For the sake of clarity, the addition of any New Products shall not affect
the Minimum Sales of Kits required under Schedule 2 hereof. If requested by the Company, the Distributors shall use best efforts to obtain the Registration for such New Products as soon as possible. 

 

	 	5.3.	If the Parties cannot agree pricing for New Products within ninety (90) days of the Company notifying Distributors thereof, such New Products shall be deemed not to be Products under this Agreement and shall be
excluded from this Agreement, provided however that the Company may not distribute the New Products in the Territory through another distributor under pricing and other terms and conditions better, when viewed in their entirety, than those offered
to Distributors as a last bid during the Term. For the avoidance of doubt Distributors shall continue to be entitled to sell Products (but not New Products if agreement is not reached on the terms for the addition of New Products to this Agreement)
during the Term of this Agreement. 

  

	 	5.4.	The Company shall reasonably promptly after determining it will be marketing and selling New Consumables (and will be able to sell them for use in the Territory) notify Distributors thereof and not unreasonably refuse
to agree to such New Consumables from time to time being included as Products under this Agreement subject to reaching agreement in writing with Distributors as to pricing and other terms therefor. 

 

	6	PRICES AND PAYMENT 

  

	 	6.1.	The prices payable to the Company by the Distributors for the Kits and OI Accessories are the prices shown in Schedule 1. The Company shall be entitled to increase the prices on Kits and OI Accessories on an annual
basis in line with the UK Retail Price Index. Before implementing any increase, however, the Company will meet with the Distributors to review the pricing of the Kits and OI Accessories including, without limitation, any proposed increases arising
under the Company’s entitlement to increase the prices on Kits and OI Accessories on an annual basis in line with the UK Retail Price Index. This review will occur during the third quarterly meeting in each Contract Year, with the first meeting
being December 2014. 

  

	 	6.2.	The Company may increase the prices applicable to Consumables as set out in Schedule 3 in each Contract Year (including the first Contract Year) by giving at least thirty (30 days prior written notice to Distributor.
Such new prices will take effect at the end of the thirty (30) day notice period. The Distributor acknowledges that the Company has no control over the cost of the Consumables and that the Company shall be free to pass on any increase in the
cost of Consumables. 

  

	 	6.3.	Delivery of ordered Kits, OI Accessories, and Other Products shall take place Ex Works (lncoterms 2010). However, if requested by the Distributors, the Company shall arrange carriage, insurance and freight of ordered
Kits, OI Accessories and Other Products to the Distributors’ premises on the Distributors’ behalf and at the Distributors’ risk and cost. 

  
 - 13 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	6.4.	The Distributors must bear any and all expenses, costs and charges incurred by them in the performance of their obligations under this Agreement, except those, if any, that the Company has previously expressly agreed to
bear. 

  

	 	6.5.	The Company may invoice upon delivery. Unless the Parties agree otherwise the Distributors shall pay the full amount invoiced to them by the Company in US Dollars within 45 days of delivery of the Products ordered.

  

	 	6.6.	The Distributors shall not be entitled by reason of any set-off, counter-claim, abatement, or other similar deduction to withhold payment of any amount due to the Company. 

 

	 	6.7.	The Distributors shall be responsible for the collection, remittance and payment of all taxes, charges, levies, assessments and other fees of any kind imposed by governmental or other authority in respect of the
purchase, sale or other distribution of the Products. 

  

	 	6.8.	The Company reserves the right to decline to accept any further order for the Kits or Other Products and to refuse shipment of any order for the Kits or Other Products if any payment due to the Company under the terms
of this Agreement is not made within 10 days of that payment becoming due. Notwithstanding the foregoing, if payment is not made as a result of a delay in clearing the Kits or Other Products through customs, and such delay is beyond the control of
Distributors, then Company’s right to decline to accept any further orders or to refuse shipment of any orders for Kits or Other Products shall not arise until the 30th day following the date payment became due.

 

	 	6.9.	Without prejudice to any other right or remedy, the Company may extend credit to the Distributors on such terms and conditions which Company may provide to the Distributors. 

 

	 	6.10.	Without prejudice to any other right or remedy, if a Party fails to pay any amount due under this Agreement, it shall pay interest on the unpaid amounts at a rate of four per cent per annum above the base rate from time
to time of Barclays Bank plc (or, if such rate is not published or is otherwise unavailable, the Bank of England’s base rate) from the due date until the date of receipt of payment by the other Party (both before and after judgment).

  

	 	6.11.	In the event that the exchange rate between RMB (YUAN) and US Dollar published at 12:00 noon China time by the People Bank of China on the relevant date changes by more than 20% in either direction compared to the
exchange rate on the Effective Date, the Parties agree to meet to discuss in good faith if any change to transfer price and/or Minimum Quantities (as set forth in the schedules) is appropriate. Nothing contained herein shall obligate any Party to
agree to any change of pricing or Minimum Quantity. 

  

	7	THE COMPANY’S DUTIES 

  

	 	7.1.	The Company undertakes and agrees with the Distributors that it will observe and perform the terms and conditions set out in this Agreement and in particular will: 

 

	 	7.1.1.	supply such of the Technology to the Distributors which in the Company’s sole but reasonable discretion is necessary to enable the Distributors to apply for the Registration, to label the Kits subject to 3.1.21 and
to distribute the Kits effectively and to carry out its duties under this Agreement; 

  
 - 14 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	7.1.2.	make available without charge to the Distributors reasonable technical assistance including the results of all clinical trials conducted by the Company on the Products to assist the Distributors to distribute the
Products; 

  

	 	7.1.3.	make available suitable personnel for reasonable periods for the training of suitably qualified personnel of the Distributors concerning the nature and use of the Products. The Distributors shall be responsible for all
costs and expenses of this training (including without limitation all out-of-pocket expenses for any Company personnel that travel to China to assist with training) unless otherwise agreed in writing; 

 

	 	7.1.4.	inform the Distributors of details of advertising and promotional programs relating to the Kits and, as applicable, Other Products and supply the Distributors with reasonable electronic or digital copies of advertising
and promotional material relating to the Kits and, as applicable, Other Products without charge so that the Distributors can produce literature in Mandarin for the Territory at the Distributors’ expense; 

 

	 	7.1.5.	approve or give reasons for any disapproval in relation to any material submitted pursuant to clause 3.1.19 within 28 days of receipt; 

 

	 	7.1.6.	participate with the Distributors in fairs and exhibitions in the Territory, where previously agreed; 

  

	 	7.1.7.	at the Company’s sole discretion provide adequate numbers of Kits to the Distributors at no cost to enable the Distributors to obtain the Registration pursuant to Registration Agreement, provided that the
Distributors may not transfer such Kits to any other person or entity without the express prior written consent of the Company, which consent may be subject to reasonable conditions; 

 

	 	7.1.8.	provide the Distributors with such data as may be reasonably requested that are in the possession of the Company to support the Registration procedure in the Territory. 

 

	 	7.2	The Company shall continue to participate and cooperate in actions in China, including efforts to resolve such actual, alleged, or threatened the intellectual property Infringement, at its own expense, associated with
the Kits and Other Products and shall keep Distributor reasonably informed of the status of such actions. 

  

	 	7.3	During the Term, the Company and its Affiliates will not directly or indirectly sell in the Territory any products used for the diagnosis of tuberculosis infection in humans competitive to the Products, whether by way
of establishing a wholly-owned foreign company or equity joint venture, contractual joint venture, trust company, or otherwise. 

  
 - 15 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	8	LIMITATION OF LIABILITY 

  

	 	8.1.	Nothing in these conditions will operate to exclude or limit the liability of the Company for death or personal injury arising out of its negligence or for its fraud in any way whatsoever. 

 

	 	8.2.	Subject to clause 8.1, under no circumstance will the Company have any liability (whether in contract, tort (including negligence) or otherwise) under or in connection with this Agreement for: 

 

	 	8.2.1.	indirect, special or consequential losses of any nature; 

  

	 	8.2.2.	wasted or lost management time or time of other employees, loss of profits, contracts or business, loss of goodwill or loss of anticipated savings; or 

 

	 	8.2.3.	any increased costs or expenses. 

  

	 	8.3.	Subject to clause 8.1, the Company’s maximum total liability (whether in contract, tort (including negligence) or otherwise) under or in connection with this Agreement, will not exceed £25,000.

  

	 	8.4.	The express terms of this Agreement are in lieu of all warranties, conditions, terms, representations, undertakings and obligations implied by statute, common law, custom, trade usage, course of dealing or otherwise,
all of which are excluded to the fullest extent permitted by law. 

  

	9	CONFIDENTIALITY 

  

	 	9.1.	Each party agrees and undertakes that after execution of this Agreement it will keep confidential and will only use for the purposes of this Agreement nor without the prior written consent of the other party disclose to
any third party (other than as required by law or a body of competent jurisdiction) all information of a confidential nature whether written or oral (including the terms of this Agreement, the Technology, other trade secrets and information of
commercial value) which may become known to that party from the other party (“confidential information”). Notwithstanding the foregoing, the Company shall be entitled to disclose any information from one Distributor to the other
Distributor without any liability hereunder. The obligations of confidentiality and non-use set forth in this Agreement shall not apply to any portion of the confidential information which was public knowledge or already known to that party at the
time of disclosure or subsequently becomes public knowledge other than by breach of this Agreement or subsequently comes lawfully into the possession of that party from a third party. For this purpose, a distributor shall not be deemed to have
received information from a third party if the source of information is, directly or indirectly, the other Distributor. 

  
 - 16 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	9.2.	To the extent necessary to implement the provisions of this Agreement each party may disclose the confidential information to those of its officers, employees, sub-contractors and agents as may be reasonably necessary
or desirable in order to accomplish the matters contemplated by this Agreement; provided that before any such disclosure each party shall (i) make those persons aware of their obligations of confidentiality under this Agreement and secure the
written agreement of those persons to protect the confidentiality of such information and (ii) at all times procure compliance by those persons with such confidentiality obligations. 

 

	10	INTELLECTUAL PROPERTY 

  

	 	10.1.	The Company hereby grants to Distributors the co-exclusive right, along with the Company, in the Territory to use the Trademarks solely in the promotion, advertisement and sale of the Kits and OI Accessories in strict
accordance with the terms of and for the duration of this Agreement. The Distributors shall undertake all such actions and execute all such instruments and documents as are necessary or desirable in order to register or give effect to the license of
the Trademarks pursuant to any applicable law. 

  

	 	10.2.	The Kits and OI Accessories shall be sold under the Trademarks and on all containers and advertisements for the Kits and OI Accessories the symbol ® shall be used
in conjunction with the registered Trademarks or “TM” in conjunction with any Trademark applications in the Territory. 

  

	 	10.3.	All representations of the Trademarks which the Distributors propose to use shall first be submitted to the Company for, and shall not be used by Distributors without, the Company’s prior written approval.

  

	 	10.4.	The Distributors shall not, without the prior written consent of the Company, alter or make any addition to the labeling or packaging of the Kits or OI Accessories displaying the Trademarks, and shall not alter, deface
or remove in any manner any reference to the Trademarks, any reference to the Company or any other name attached or affixed to the Kits or their packaging or labeling other than to add the Distributor’s name and contact details, or as otherwise
may be required by applicable law in order to comply with the Registration. 

  

	 	10.5.	The Company makes no representation or warranty either as to the validity or enforceability of the Trademarks or as to whether the same infringe upon any intellectual property rights of third parties in the Territory.

  

	 	10.6.	Trademark infringement 

  

	 	10.6.1.	Each party shall promptly give notice in writing to the other in the event that it becomes aware of: 

  

	 	10.6.1.1.	any infringement or suspected infringement within the Territory of the Trademarks or any other intellectual property rights in or relating to the Products; and 

  
 - 17 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	10.6.1.2.	any claim that any Product or the manufacture, use, sale or other disposal of any Product within the Territory, whether or not under the Trademarks, infringes the rights of any third party. 

 

	 	10.6.1.3.	In the case of any matter falling within clause 11.6.1.2: 

  

	 	10.6.1.4.	the Company shall in its absolute discretion determine what action, if any, shall be taken in respect of the matter; 

  

	 	10.6.1.5.	the Company shall have sole control over and shall conduct any action as it shall in its discretion deem appropriate; 

  

	 	10.6.1.6.	the Company shall pay all costs in connection with that action and shall be entitled to all damages and other sums which may be paid or awarded as a result of any such action; and 

 

	 	10.6.1.7.	the Distributors shall, at the request and expense of the Company, provide all reasonable assistance to the Company (including but not limited to the use of its name in or being joined as a party to proceedings) in
connection with any action to be taken by the Company pursuant to this clause provided that that Distributor is given such indemnity as it may reasonably request against any damage to its name. 

 

	 	10.7.	As between the Company and the Distributors, the Distributors acknowledge and accept that the Company is the owner of all of the Intellectual Property Rights in and in connection with the Products, including without
limitation the Technology and the Trademarks, and the Distributors shall not represent in any way that they, or either of them, has any right or title to the ownership of such Intellectual Property Rights. 

 

	11	PRODUCT LIABILITY AND INSURANCE 

  

	 	11.1.	Each of the Distributors shall, immediately after it becomes aware of any liability incurred by the Distributors in respect of damage to property, death or personal injury arising from any fault or defect in the
materials or workmanship of the Kits, OI Accessories or, as applicable, of any Other Products and any reasonable costs, claims, demands and expenses arising out of or in connection with that liability (a “Relevant Claim”):

  

	 	11.1.1.	immediately give notice to the Company of the details of the matter; 

  
 - 18 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	11.1.2.	afford access to the Company and permit copies to be taken of any materials, records or documents as the Company may require to take action under clause 11.1.3; 

 

	 	11.1.3.	allow the Company the exclusive conduct of any proceedings and/or take whatever action at Company’s sole cost, as the Company shall direct to defend or resist the matter, including the use of professional advisers
nominated by the Company; and 

  

	 	11.1.4.	not admit liability or settle the matter without the written consent of the Company. 

  

	 	11.2.	The Company shall maintain product liability insurance for the Term of this Agreement of not less than £1,000,000.00 in aggregate per annum with a reputable insurer and shall provide a copy of the insurance policy
and proof of payment of the current premium to the Distributors upon request by the latter. 

  

	 	11.3.	The Distributors undertake to maintain appropriate up-to-date and accurate records in compliance with the Company’s quality assurance procedures as amended from time to time to enable the immediate recall of any
batches of the Kits or OI Accessories or any of them or, as applicable, any Other Product from the retail and/or wholesale markets. These records shall include records of deliveries to customers (including details of batch numbers, delivery date,
name and address of customer, and telephone number and fax or telex number if available). 

  

	 	11.4.	Except where a recall or other action to withdraw Kits, OI Accessories or, as applicable, any Other Products from the market results from Distributor’s directions, actions or inactions, the Company shall reimburse
Distributors for reasonable and necessary out-of-pocket costs incurred by Distributors in recalling as a matter of urgency any quantities of the Kits, OI Accessories or any of them or, as applicable, any Other Products from the retail and/or
wholesale market. Reasonable and necessary out-of-pocket costs shall include costs incurred in retrieving Kits, OI Accessories or Other Products from the market, such as postage, freight, and similar costs, as well as the cost of replacement Kits,
OI Accessories, and, if applicable, Other Products that are subject to recall. 

  

	12	TERM AND TERMINATION 

  

	 	12.1.	This Agreement shall commence on the Effective Date and continue for the Term subject to the provisions for earlier termination contained in this Agreement. Provided this Agreement has not been terminated, as provided
for herein, prior to the scheduled end of the Term, the Distributors shall have the option to extend this Agreement, subject to mutually acceptable terms and conditions being agreed. Notice of the Distributors’ exercise of the option to extend
shall be given between no earlier than six (6) months prior to the scheduled end of the Term and no later than three (3) months prior to the scheduled end of the Term. Upon the giving of such notice, the parties agree to promptly commence
discussions on acceptable terms and conditions for renewal. For avoidance of doubt, the Distributors shall have the option to extend only at the end of the initial seven (7) year Term. 

  
 - 19 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	12.2.	The Company may terminate this Agreement on ninety (90) days’ written notice at any time following the occurrence of either of the following events: (a) Fosun Industrial Co., Limited (the
“Noteholder”) sells, transfers or otherwise disposes of more than 50% of its holdings in Oxford Immunotec Global PLC; or (b) the Company repays in full all amounts due and owing under the Convertible Note dated October
    , 2013 by and between the Company and the Noteholder (the “Note”); provided, however, that Company’s right of termination as set forth in this Clause 12.2(b) shall not apply if the Company’s repayment of
the Note is made under the circumstances described in Section 3.3 of the Note. 

  

	 	12.3.	Without prejudice to any other rights to which it may be entitled, either party may give notice in writing to the other terminating this Agreement with immediate effect if: 

 

	 	12.3.1.	the other party commits any material breach of any of the terms of this Agreement if irremediable or if such a breach is remediable fails to remedy that breach within 30 days of that party being notified in writing of
the breach; 

  

	 	12.3.2.	if an order is made or a resolution is passed for the winding up of the other party or if an order is made for the appointment of an administrator to manage the affairs, business and property of the other party or if a
receiver is appointed of any of the other party’s assets or undertaking or if circumstances arise which entitle the Court or a creditor to appoint a receiver or manager or which entitle the Court to make a winding-up order or if the other party
takes or suffers any similar or analogous action in consequence of debt. 

 For purposes of this Clause 12.3, the Distributors
shall be treated as one party, provided that the Company shall have the right to terminate for a breach under Clause 12.3.1 by either Distributor or if a condition described in Clause 12.3.2 occurs with respect to either Distributor. 

 

	 	12.4.	Without prejudice to any other rights to which it may be entitled, the Company may give notice in writing to the Distributors terminating this Agreement with immediate effect if: 

 

	 	12.4.1.	the Distributors fail to pay any sum due under this Agreement within 30 days following its due date; 

  

	 	12.4.2.	there is a change of control (in the sense of the ability to direct the affairs of the Distributor whether by virtue of the ownership of shares, contract or otherwise) of either Distributor or any affiliate that
controls either Distributor; 

  

	 	12.4.3.	either Distributor purports to assign its rights or obligations under this Agreement without the Company’s consent in accordance with clause 16; 

 

	 	12.5.	If, despite the reasonable and best efforts of Distributors, the Products do not successfully achieve Registration, in whole or in part, the parties will meet and confer to determent whether this Agreement shall
continue with respect to the Products subject to Registration or shall be terminated. 

  
 - 20 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	12.6.	The Company, in its sole discretion, may terminate the Distributorship Agreement if the Distributors fail in any Contract Year to purchase the Minimum Quantity as set out in Schedule 2 for that Contract Year.
Company’s failure to terminate Distributors under this Section despite failure of Distributors to purchase the Minimum Quantity shall not be construed as or otherwise prejudice Company’s rights under this paragraph. 

 

	 	12.7.	In determining whether Distributors have satisfied the Minimum Quantity purchases for any given Contract Year, each Contract Year shall be treated on a separate basis. Any purchases which exceed the Minimum Quantity
purchases in any Contract Year may not be applied to offset any deficiencies in the Minimum Quantity purchases for the prior or subsequent Contract Year. A firm order for Kits will be treated as a purchase in a Contract Year even though delivery has
not yet been made so long as delivery is made, in full or in part, during the same Contract Year in which the firm order was placed. Likewise, to satisfy the Minimum Purchase obligations, it is not necessary that the Distributors have fully paid the
purchase price therefor during the Contract Year in question. If the Company is unable, due to a force majeure event, to deliver the full quantity of Kits ordered by the Distributors, and such inability of the Company results in a shortfall in
Distributors’ Minimum Quantity purchases in a Contract Year, the Company shall not be entitled to terminate this Agreement based on that shortfall. 

  

	13	CONSEQUENCES OF TERMINATION OR EXPIRY 

  

	 	13.1.	Upon the expiration of this Agreement or the termination of this Agreement from any cause: 

  

	 	13.1.1.	the Distributors shall promptly return to the Company or otherwise dispose of as the Company may require the Technology and all other documents, papers and materials whatsoever in the possession, power, custody or
control of the Distributors relating to the Products, the Company’s Intellectual Property or the business of the Company; 

  

	 	13.1.2.	the Distributors shall promptly return to the Company or otherwise dispose of as the Company may require all advertising and promotional material in the possession, power, custody or control of the Distributors relating
to the Kits, OI Accessories or, as applicable, Other Products as far as they have been made available to the Distributors by the Company free of charge; 

  

	 	13.1.3.	in respect of any stocks of Kits, OI Accessories or, as applicable, Other Products held by the Distributors upon termination the Distributors shall continue to have the right for the next six months following
termination to distribute the Kits (or, as applicable, Other Products) for sale in the Territory on the terms and conditions of this Agreement; 

  

	 	13.1.4.	without prejudice to the provisions of Clause 13.1.3 above the Distributors shall cease to hold themselves out as having any right to distribute the Kits, OI Accessories or, as applicable, Other Products;

  
 - 21 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	 	13.1.5.	subject to clause 13.1.3, all other rights and licenses of the Distributors under this Agreement shall terminate; 

  

	 	13.1.6.	the termination of this Agreement shall not of itself give rise to any liability on the part of the Company to pay any compensation to the Distributors for loss of profits or goodwill; 

 

	 	13.1.7.	if the termination shall occur before Registration, then (subject to clause 13.1.3) the Distributors undertake to immediately cease all distribution of (and shall not authorise, permit or suffer any third party to
manufacture or distribute) any Kits or OI Accessories; and 

  

	 	13.1.8.	the Distributors shall procure the compliance of all agents, sub-contractors and Distributor Affiliates with the termination obligations of Distributors hereunder. 

 

	 	13.2.	The Company shall be entitled to cancel all orders placed by the Distributors prior to the termination date, whether or not such orders have been accepted by the Company, without incurring any liability of whatsoever
nature to the Distributors. 

  

	 	13.3.	Notwithstanding anything contained elsewhere in this Agreement, the provisions of clauses 1, 3.1.3, 3.1.22, 7.3, 8, 9, 11.4, 14, 18 and 19 shall survive the expiry or termination of this Agreement howsoever caused and
shall continue thereafter in full force and effect. 

  

	 	13.4.	Termination shall not affect the accrued rights of the parties arising in any way out of this Agreement as at the date of termination. 

 

	 	13.5.	All rights granted to the Distributors in respect of the Trademarks (if any) shall immediately terminate and the Distributors shall forthwith cease to use and not recommence use of the Trademarks worldwide.

 To the maximum extent permitted by the applicable law, upon the expiration or termination of this Agreement, Distributors
shall not under any circumstances be entitled to compensation of damages or any kind, whether on account of the loss by Distributors of present or prospective sales, investment, compensation or goodwill. Each of the Distributors, for itself and on
behalf of each of its employees, agents, subcontractors and representatives, hereby waives any rights which may be granted to it or them under the laws and regulations of the Territory, including, without limitation, any claim for compensation or
indemnification (a) for its loss of business or goodwill, (b) based on unjust enrichment to the Company and (c) with respect to any damage incurred by it or by them as a result of termination of its rights under this Agreement.
Distributors shall indemnify and keep indemnified the Company from and against all Losses incurred as a result of, or in connection with, any claim by or liability to Distributors or any employee, agent, sub-contractor or representative of
Distributors under any applicable agency, termination, employment, social security or other similar applicable laws. The Company shall, at its cost, defend, indemnify and hold harmless the 

  
 - 22 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 
distributor and its Affiliates, and their respective members, managers, directors, employees, officers and agents from and against any and all Losses arising out of: (i) a breach by the
Company of this Agreement, or (ii) the gross negligence or willful misconduct of the Company. Distributors shall, at their cost, defend, indemnify and hold harmless the Company and its Affiliates, and their respective members, managers,
directors, employees, officers and agents from and against any and all Losses arising out of: (x) a breach by Distributors of this Agreement, or (y) the gross negligence or willful misconduct of the Distributors. 

 

	14	SUPERVENING LAWS AND FORCE MAJEURE 

  

	 	14.1.	The rights and obligations of the parties under this Agreement shall be subject to all applicable laws, orders, regulations, directions, restrictions and limitation of governments or other bodies. 

 

	 	14.2.	If any other law, order, regulation, direction, restriction or limitation or any treaty or other international agreement or the juridical construction of any of them shall, after the Commencement Date, substantially
alter the relationship between the Company and the Distributors or the balance of advantages derived from such relationship then, at the request of the adversely affected party, the Company and the Distributors agree to negotiate in good faith to
modify this Agreement to restore the situation if practicable or to compensate for such alteration if not. Should they fail to reach such agreement within three months after the request has been received by the party not affected, either the Company
or the Distributors may terminate this Agreement forthwith without incurring any liability. 

  

	 	14.3.	If there is any total or partial failure of performance by any party by any cause whatsoever beyond the reasonable control of the party (a force majeure event) then once the cause has been notified by that party to the
other such failure shall not be deemed to be a breach of this Agreement which shall continue in suspense or in partial performance for the period during which such cause exists. If the cause of such suspension or partial performance continues for a
period of more than three (3) months and substantially effects the operation of the Agreement then the Company or the Distributors not claiming relief under this Clause shall be at liberty to terminate this Agreement on giving to the other 90
days notice of its intention to do so and this Agreement shall terminate on expiration of such notice period. 

  

	15	ASSIGNMENT 

 The Distributors shall not assign, transfer, sub-contract or in any manner convey the
benefit of this Agreement to any person or persons whatsoever without the prior written consent of the Company. The Company may assign this Agreement in connection with a merger, consolidation, or a sale or transfer of all or substantially all of
the assets to which this Agreement relates. 

  
 - 23 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

	16	MISCELLANEOUS 

  

	 	16.1.	This Agreement supersedes all prior agreements, negotiations and discussions between the parties relating to it. Each party acknowledges that in entering into this Agreement it is not relying upon any prior written or
oral term sheet, letter agreement, draft, assurance, promise or any other prior arrangement of any nature. All schedules are incorporated herein by reference. 

  

	 	16.2.	This Agreement shall not be varied, amended or supplemented except in writing, executed by the duly authorised representatives of both the Company and the Distributors. 

 

	 	16.3.	The failure of either the Company or the Distributors at any time to enforce the terms and provisions or conditions of this Agreement shall not be construed as a waiver of the same or the right of such party to enforce
the same. 

  

	 	16.4.	The obligations of Distributors hereunder are joint and several. 

  

	17	NOTICES 

 Any notice to be given under this Agreement must be in writing, may be delivered to the other
party by any of the methods set out in the left hand column below and will be deemed to be received on the corresponding day set out in the right hand column. 
  

			
	Method of service	  	Deemed day of receipt
		
	By hand	  	The day of delivery
		
	By pre-paid international business post / courier	  	The fourth Business Day after posting
		
	By fax (provided the sender’s fax machine confirms complete and error-free transmission to the correct fax number)	  	The next Business Day after sending.

 The parties’ representatives for the receipt of notices are as follows (until altered by notice given in accordance with
this clause): 
  

			
	For the Company:	  	For the Distributors
	Chief Executive Officer	  	Mr. Joel Y Zhang
	Fax number: +44 1235 - 442781	  	Fax number: +86 21 60765710

  

	18	LANGUAGE AND LAW; DISPUTE RESOLUTION 

 This Agreement is written in the English language and the
construction, validity and performance of this Agreement shall be governed by English law. All notices permitted or required by this Agreement, and all reports, forecasts and other exchanges between the Parties shall be in English, except to the
extent otherwise expressly provided in. 

  
 - 24 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 Any dispute, controversy or claim arising out of or relating to this Agreement, or the interpretation,
breach, termination or validity hereof, shall be resolved through consultation. Such consultation shall begin immediately after one Party hereto has delivered to the other Party hereto a written request for such consultation. For purposes of the
dispute resolution provisions of this Agreement, the Distributors shall be considered to be one Party. If within thirty (30) days following the date on which such notice is given the dispute cannot be resolved, the dispute shall be submitted to
arbitration upon the request of either Party with notice to the other Party. The arbitration shall be conducted in Hong Kong under the auspices of the Hong Kong International Arbitration Centre (the “Centre”). There shall be three
arbitrators. Each of the Parties shall select one arbitrator within thirty (30) days after giving or receiving the demand for arbitration. The Chairman of the Centre shall select the third arbitrator, who shall be qualified to practice English
law. The arbitration proceedings shall be conducted in English. The arbitration tribunal shall apply the Arbitration Rules of the Centre in effect at the time of the arbitration. The arbitrators shall decide any dispute submitted by the Parties to
the arbitration strictly in accordance with English law. The award of the arbitration tribunal shall be final and binding upon the Parties, and any Party may apply to a court of competent jurisdiction for enforcement of such award. Each Party shall
cooperate and use their respective best efforts to take all actions reasonably required to facilitate the prompt enforcement in the PRC or in any other jurisdiction of any arbitration award made by the tribunal. A Party shall be entitled to seek
preliminary injunctive relief from any court of competent jurisdiction pending the constitution of the arbitral tribunal. 
 Signature Page Follows 

IN WITNESS that this Agreement has been executed by duly authorized officers of the parties to the Agreement the day and year first above written. 

For and on behalf of Oxford Immunotec Limited 
  

			
	Signature:	 	 /s/ Dr Peter Wrighton-Smith

		
	Name:	 	Dr Peter Wrighton-Smith
		
	Title:	 	CEO
		
	Date:	 	 8th October 2013

		
	Place:	 	 Abingdon, UK

  
 - 25 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 For and on behalf of Shanghai Fosun Long March Medical Science Co. Ltd. 

 

			
	Signature:	 	 /s/ Zhu Yao Yi

		
	Name:	 	Mr Zhu Yao Yi
		
	Title:	 	Chairman
		
	Date:	 	 Oct. 14, 2013

		
	Place:	 	 Shanghai

 For and on behalf of Shanghai Xin Chang Medical Device Co. Ltd. 

 

			
	Signature:	 	 /s/ Zhu Yao Yi

		
	Name:	 	Mr Zhu Yao Yi
		
	Title:	 	Chairman
		
	Date:	 	 Oct. 14, 2013

		
	Place:	 	 Shanghai

  
 - 26 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 SCHEDULE 1 

Price of the T-SPOT.TB 24 test assay kit -TB-300 is $[***] per kit, exclusive of VAT. 

All sales under this Agreement shall be made EXW (Incoterms 2010) Oxford Immunotec’s principal manufacturing facility in Oxfordshire, United Kingdom.

 The Price of Kits shall be adjusted at the end of each Contract Year in accordance with Clause 6.1 of the Distributorship Agreement. 

[***] 

  
 - 27 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 SCHEDULE 2 

Minimum Quantities 
  

																													
	 Year
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
								
	 Growth Rate
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
								
	 Minimum Kit Purchase
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 

 The Distributors’ minimum required purchases from the Company shall be as follows: 

If any other Product (other than Consumables) becomes available for the Distributors’ purchase under this Agreement, the Parties agree to negotiate in
good faith to establish appropriate Minimum Quantity purchase obligations for each such Product. 

  
 - 28 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 SCHEDULE 3 

Consumables 
  

									
	Item	  	Product Code	  	Pack size	  	Price 2014	 
				
	 AIM V
	  	AV.200/50	  	1 x50 ml	  	 	US $[***	] 
	 AIM V
	  	AV.200/500	  	1 x 500 ml	  	 	US $[***	] 

 Prices for any Other Product which becomes available for the Distributors to purchase under this Agreement shall be agreed
between the Parties from time to time. 
 All prices shown for the Consumables listed above are EXW (ex-works) under Incoterms 2010. 

OI Accessories 
  

									
	Item	  	Product Code	  	Pack size	  	Price 2014	 
				
	 T-Cell Xtend 
	  	TTK.610	  	1 pack	  	 	US $[***	] 
	 Leucosep Tubes
	  	LTK.615	  	1 x 500 ml	  	 	US $[***	] 

 [***] 
 All prices shown for the
OI Accessories listed above are EXW (ex-works) under Incoterms 2010. 

  
 - 29 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 Schedule 4 

Specification 
 Intended Use 

The T-SPOT®.TB assay is an in vitro diagnostic test for the detection of effector T cells that respond to stimulation by Mycobacterium
tuberculosis antigens and is intended for use as an aid in the diagnosis of tuberculosis (TB) infection. The T-SPOT.TB assay is a simplified enzyme-linked immunospot (ELISPOT) method which enumerates individual TB-specific activated
effector T cells. 
 Principles of the Procedure 

Peripheral blood mononuclear cells (PBMCs) are separated from a whole blood sample and washed to remove any sources of background interfering signal. The PBMCs
are then counted so that a standardised cell number is used in the assay. This ensures that even those who have low T cell titres due to weakened immune systems (the immunocompromised and immunosuppressed) have adequate numbers of cells added to the
microtitre wells. The washing and counting stages as well as the ELISPOT technique provide superior performance for the detection of TB disease and latent TB infection. 

Limitations 

 ̈ For in vitro diagnostic use only. 

 ̈ For professional use only. 

 ̈ Store the unopened kit at 2-8°C. The kit must not be used beyond the expiry date on the kit label. 

 ̈ Store opened kit components at 2-8°C. Components must be used within 8 weeks of opening, such period
ending no later than the expiry date on the kit label. 
  ̈ Do not mix components from different kit lots.

  ̈ Read the assay instructions carefully before use. 

 ̈ Observe aseptic technique to avoid contaminating the reagents, assay wells, cell suspensions and cell
culture media. 
  ̈ Variation to the stated pipetting and washing techniques, incubation times and/or
temperatures may influence the actual results obtained and should be avoided. 
  ̈ Blood should be collected
and progressed into the assay within 8 hours. This time limitation may be overcome by using the T-Cell Xtend® reagent (available from Oxford Immunotec). 

When the T-Cell Xtend reagent is used with the T-SPOT.TB assay, the sample storage time is increased to 32 hours. 

 ̈ Store and transport blood samples to the laboratory at room temperature (18-25°C). If the T-Cell
Xtend reagent is to be used, samples can be transported and stored at 10-25°C. Do not refrigerate or freeze whole blood samples. 
  ̈ The T-SPOT.TB assay should be used and interpreted only in the context of the overall clinical picture. 

 ̈ A negative test result does not exclude the possibility of exposure to or infection with M.
tuberculosis. 
  ̈ ESAT-6 and CFP10 antigens are absent from BCG strains and from most environmental
mycobacteria, with the exception of M. kansasii, M. szulgai, M. marinum3,4 and M. gordonae. 
 Safety Warnings and
Precautions 
 Care should be taken when handling material of human origin. All blood samples should be considered potentially infectious. 

  
 - 30 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 Handling of blood samples and assay components, their use, storage and disposal should be in accordance with
procedures defined in appropriate national biohazard safety guidelines or regulations. 
 Care should be taken when working with chemicals. All chemicals
should be considered potentially hazardous. 
 Materials Provided 

The T-SPOT.TB 8 kit contains: 
 1. 1 microtitre plate: 96
wells, supplied as 12 x 8-well strips in a frame, coated with a mouse monoclonal antibody to the cytokine interferon gamma (IFN-g). 

2. 2 vials (0.8mL each) Panel A: contains ESAT-6 antigens, bovine serum albumin and antimicrobial agents. 

3. 2 vials (0.8mL each) Panel B: contains CFP10 antigens, bovine serum albumin and antimicrobial agents. 

4. 2 vials (0.8mL each) Positive Control: contains phytohaemagglutinin (PHA), for use as a cell functionality control, bovine serum albumin and antimicrobial
agents. 
 5. 1 vial (50μL) 200x concentrated Conjugate Reagent: mouse monoclonal antibody to the cytokine
IFN-g conjugated to alkaline phosphatase. 
 6. 1 bottle (25mL) Substrate Solution: ready to use
BCIP/NBTplus solution. 
 7. Instructions for Use, which are found on the CD together with the MSDS, Technical Handbook, Visual Procedure Guide, T-SPOT cell
dilution calculator, conjugate dilution calculator, centrifuge speed calculator and the T-SPOT.AutoReporter programme. 
 Storage 

Store all components of the kit at 2-8°C. 
 Avoid prolonged
exposure of the Substrate Solution to light. 
 Stability 

The components of the kit are stable up to the expiry date printed on the kit box, when stored and handled under the recommended conditions. 

Equipment and Materials Required but Not Provided 
 1.
8-well strip plate frame (available from Oxford Immunotec). 
 2. Class II microbiological cabinet (recommended). 

3. Blood collection tubes, such as Vacutainer® CPTTM* (available from Oxford Immunotec) or heparinised tubes. 

4. FICOLL-PAQUE* PLUS or alternative PBMC separation materials. 

5. The T-Cell Xtend reagent (available from Oxford Immunotec) may be used with samples collected more than 8 hours earlier. 

6. Leucosep tubes may be used to simplify the separation of PBMCs using the FICOLL* method. 

7. Centrifuge for preparation of PBMCs (capable of at least 1800xg and able to maintain the samples at room temperature (18-25°C)). 

8. Equipment and reagents to enable counting of PBMCs; either manually using Trypan Blue and a haemocytometer on a microscope or automatically using a
suitable haematology analyzer. 
 9. A humidified incubator capable of 37 ± 1°C with a 5% CO2 supply. 

10. A microtitre plate washer or equipment to manually wash plates. 

11. Pipettes and sterile pipette tips. 
 12. Sterile PBS
solution: such as GIBCO® 1x D-PBS (Invitrogen; catalogue number 14040-091). 
 13. Distilled or deionised water. 

14. A means of reading the plate such as a microscope, digital microscope, magnifying glass or plate imager. 

15. Sterile cell culture medium such as GIBCO AIM V® (Invitrogen; catalogue number 31035-025): the use of this serum free medium for the incubation step
is strongly recommended. RPMI 1640 

  
 - 31 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 
(Invitrogen; catalogue number 21875-034) may be used in the initial sample preparation steps only. It is recommended that cell culture media are stored in appropriate aliquots and excess material
is discarded after use. Cell culture media should be pre-warmed to 37°C before use with the T-SPOT.TB assay. 
  

	*	Vacutainer and CPT are trademarks of Becton, Dickinson and Company. 

 For firm orders placed accordance with
this Agreement as Oxford Immunotec shall supply Product with a minimum residual shelf life of 6 months (ex Milton Park) 

  
 - 32 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

 Schedule 5 

Oxford Immunotec has filed for the following trademarks: 
  

											
	 Trademark
	  	 Countries Applied for
	  	 Status
	  	 Classes
	  	 Appn / Regn

Number
	  	 Renewal date

(appln date)

						
	T-SPOT	  	 US
 United Kingdom

New Zealand
 Australia

EC
 Ukraine

Hungary
 India

Japan
 Canada

R. of Korea
 Mexico

Brazil
 Brazil

S. Africa
 Singapore

Russia
 Kazakhstan

China
 Switzerland

Philippines
 Vietnam
	  	 Registered
 Registered

Registered
 Registered

Registered
 Allowed

Allowed
 Registered

Registered
 Registered

Registered
 Registered

Registered
 Registered

Registered
 Registered

Allowed
 Registered Assigned

Registered
 Allowed

Filed
	  	 05 & 10 & 44
 05 & 10 &
44
 05 & 10 & 44
 05 & 10 & 44

05 & 10 & 44
 05 & 10 & 44

05 & 10 & 44
 05 & 10 & 42

05 & 10 & 44
 05 & 10 & 44

05 & 10 & 44
 05 & 44

05
 10

10 & 44
 05 & 10 & 44

05 & 10 & 44
 05 & 10 & 44

05
 05 & 10 & 44

05 & 10 & 44
 05 & 10 & 44
	  	 3665044
 2365985

722882
 1063310

851245
 851245

851245
 1326004

851245
 766238

851245
 1051711

829435760
 829435786

2007/22618
 851245

851245
 45514

5774956
 851245

851245
 4-13-001970
	  	 17.Jun.2014
 17.Jun.2014

17.Jun.2014
 14.Dec.2014

14.Dec.2014
 14.Dec.2014

14.Dec.2014
 14.Dec.2014

14.Dec.2014
 10.May.2025

14.Dec.2014
 3.Oct.2017

22.Dec.2019
 19.Jan.2020

4.Oct.2017
 14.Dec.2014

14.Dec.2014
 18.Dec.2018

6.Dec.2019
 14.Dec.2014

(24.Oct.2012)
 (24.Oct.2012)

						
	T-CELL XTEND	  	 US
 United Kingdom

New Zealand
 Australia

EC
 India

Japan
 Canada

R. of Korea
 Mexico

Brazil
 Brazil

S. Africa
 S. Africa

Singapore
 China

Russia
 Switzerland

Turkey
 Norway
	  	 Registered
 Registered

Registered
 Registered

Registered
 Registered

Registered
 Allowed

Registered
 Registered

Allowed
 Allowed

Registered
 Registered

Registered
 Allowed

Allowed
 Allowed

Allowed
 Allowed
	  	 01 & 05
 01 & 05

01 & 05
 01 & 05

01 & 05
 01 & 05

05
 01 & 05

05
 05

01
 05

01
 05

01 & 05
 01 & 05

05
 01 & 05

01 & 05
 01 & 05
	  	 77510877
 2484469

806121
 1271950

0980855
 1740444

0980855
 1413262

0980855
 1081521

830013652
 830013660

2008/23447
 2008/23448

0980855
 0980855

0980855
 0980855

0980855
 0980855
	  	 30.Jun.2018
 8.Apr.2018

7.May.2019
 1.Oct.2018

1.Oct.2018
 6.Oct.2018

1.Oct.2018
 17.Oct.2026

1.Oct.2018
 8.Oct.2018

27.Dec.2021
 tbc

6.Oct.2018
 6.Oct.2018

1.Oct.2018
 1.Oct.2018

1.Oct.2018
 1.Oct.2018

1.Oct.2018

1.Oct.2018

  
 - 33 - 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A 

CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED 

WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND 

EXCHANGE COMMISSION. 
  

											
		  	 Kazakhstan
 Ukraine

Taiwan
 UAE

Saudi Arabia
 Saudi Arabia

Kuwait
 Israel

Israel
 Philippines

Vietnam
	  	 Registered
 Registered

Registered
 Pending

Registered
 Registered

Registered
 Registered

Registered
 Allowed

Filed
	  	 01 & 05
 01 & 05

01
 01 & 05

05
 01

01
 01

05
 01 & 05

01 & 05
	  	 31299
 122398

1395776
 119955&56

1098/72
 1212/87

85032
 215503

215504
 0980855

4-13-001969
	  	 6.Oct.2018
 7.Oct.2018

31.Jan.2020
 (1.Oct.2008)

23.Jun.2018
 23.Jun.2018

5.Oct.2018
 6.Oct.2018

6.Oct.2018
 (24.Oct.2012)

(24.Oct.2012)

						
	Oxford Immunotec & Logo	  	 US
 United Kingdom

New Zealand Australia
 EC

India
 Japan

Canada
	  	 Allowed
 Registered

Registered
 Registered

Registered
 Registered

Registered
 Registered
	  	 05 & 10 & 44
 05 & 10 & 44

05 & 10 & 44
 05 & 10 & 44

05 & 10 & 44
 05 & 10 & 44

05 & 10 & 44
 05 & 10 & 44
	  	 78749802
 2403191

745174
 1126035

888071
 1440262

888071
 766,242
	  	 8.Nov.2015
 5.Oct.2015

5.Oct.2015
 24.Mar.2016

24.Mar.2016
 27.Mar.2016

24.Mar.2016
 10.May.2015

						
	Oxford Diagnostic Laboratories	  	USA	  	Registered	  	44	  	3880807	  	8.May.2019
						
	Oxford Diagnostic Laboratories & Logo	  	 EC
 USA
	  	 Registered
 Registered
	  	 42 & 44
 44
	  	 9144031
 4148560
	  	 1.Jun.2020
 15.Sep.2020

						
	ODL	  	EC	  	Registered	  	42 & 44	  	9143983	  	1.Jun.2020
						
	T-CPOT.Tb	  	Russian characters	  	Registered	  	5 & 10	  	442360	  	29.Jan.2020
						
	

	  	Japanese characters	  	Registered	  	5	  	2011-0131780	  	17.Feb.2022
						
	Gammaspot	  	United Kingdom	  	Lapsed	  	01 & 10	  	2282054	  	n/a
	SPOT-TB	  	United Kingdom	  	Registered	  	01 & 10	  	2293386	  	2022 (tbc)
	ACCUSPOT	  	United Kingdom	  	Lapsed	  	01 & 10	  	2282053	  	n/a
	TB-SPOT	  	 United Kingdom
 United Kingdom
	  	 Registered
 Registered
	  	 01 & 10
 05 & 44
	  	 2293399
 2417976
	  	 2022 (tbc)
 29.Mar.2016

	Clinispot	  	EC	  	Lapsed	  	5 & 10 & 42	  	2999399	  	n/a

  
 - 34 -EX-10.25

 EXHIBIT 10.25 

THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS
BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
 Marketing Authorization Holder Agreement 

This is an agreement (the “Agreement”) made on and effective as of July 29, 2011 by and between Oxford Immunotec Limited, a company organized
and existing under the laws of UK, address at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY United Kingdom (hereinafter referred to as “MANUFACTURER”, and RIKEN GENESIS CO., LTD., a company organized and existing under the laws of Japan,
address at 1-5-1 Taito, Taito-ku, Tokyo 110-8560, Japan (hereinafter referred to as “MAH”). 
 Recitals: 

MANUFACTURER is a foreign manufacturer which, at the point of this agreement, has no location in Japan and intends to obtain a special approval (Gaikoku
Tokurei Shonin Shutoku Sha) issued by the Japanese Ministry of Health, Labour and Welfare (hereinafter referred to as “MHLW”) under the Japanese Pharmaceutical Affairs Law (Yakuji Hou) (hereinafter referred to as
‘PAL”) of certain in vitro diagnostics (Taigai Shindan Yo lyakuHin), which are categorized as drugs (lyakuhin) under PAL. MANUFACTURER is desiring to designate MAH as its Designated Marketing Authorization Holder (Sen-nin
Seizou Hanbai Gyosha) (hereinafter referred to as “DMAH”) under PAL, a Pre-market Approval Holder under article 19-2 of PAL 
 MAH, which
stands for “MARKETING AUTHORIZATION HOLDER” (Seizou Hanbai Gyosha), is a Marketing Authorization Holder (Seizou Hanbai Gyosha) and is authorized to act as a DMAH under PAL. MAH is desiring to be designated and act as
MANUFACTURER’s DMAH. 

  
 1 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 In consideration of the mutual covenants and other good and valuable consideration, the receipt and legal
sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1. Designation of MANUFACTURER 

1.1 MANUFACTURER hereby designates MAH, upon the terms and conditions herein contained, to be MANUFACTURER’s DMAH with regards to PAL for certain products
(hereinafter the “PRODUCTS”) on the PRODUCT LIST, set forth in Appendix B, which is attached hereto and incorporated herein by reference. MAH hereby accepts such designation as MANUFACTURER’S DMAH. 

1.2 PRODUCTS may be added to or removed from the PRODUCT LIST by written amendment to this Agreement signed by both MANUFACTURER and MAH, but only after
applicable approval is received from MHLW, Pharmaceuticals and Medical Devices Agency (“PMDA”), a PAL-Registered Certification Body or any other authorities in Japan (hereinafter referred as “Japanese Authorities”). It is
understood and agreed that MANUFACTURER (and its affiliates) may discontinue manufacture of any of the PRODUCTS upon written notification to MAH and acceptance of such notification, submitted through MAH to MHLW, by Japanese Authorities. 

1.3 No references in this Agreement to distributors will be construed as any commitment by MANUFACTURER to select MAH as its distributor in Japan. 

2. Representations and warranties of MAH 
 2.1 MAH is and
will during the term of this Agreement remain a corporation duly organized, validly existing and in good standing under the laws of Japan. 
 2.2 MAH has,
and will utilize in performing services for MANUFACTURER under this Agreement, employees, subcontractors and/or consultants (“MAH Personnel”) with the proper skill, training, qualifications and experience to perform all activities and
responsibilities of MAH under this Agreement. MAH will be solely responsible for paying MAH Personnel and providing any employee benefits that they are owed. 

2.3 MAH does not currently act, and will not act during the term of this Agreement as DMAH regarding Tuberculosis in vitro diagnostic assays for any third
party other than the MANUFACTURER. 

  
 2 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 2.4 MAH will comply, in all material respects, with all laws and regulations applicable to its operations and
to the performance of the activities and responsibilities of MAH under this Agreement and under the Quality Agreement (referenced below), including without limitation the UK Bribery Act 2010. 

2.5 MAH represents and warrants that to the knowledge of MAH, all MAH Personnel who may perform work for MANUFACTURER under this Agreement are, in all
material respects, in good standing with the MHLW and Pharmaceuticals and Medical Devices Agency (hereinafter referred to as “PMDA”) and that they will remain, in all material respects, in good standing and in full compliance with all MHLW
and PMDA requirements throughout the term of this Agreement. 
 2.6 MAH’S WARRANTIES IN THIS SECTION 2 ARE ALL MAH’S WARRANTIES, AND ANY OTHER
EXPRESS OR IMPLIED WARRANTIES ARE HEREBY EXCLUDED. 
 3. Representations and warranties of MANUFACTURER 

3.1 MANUFACTURER hereby represents and warrants that it is and will during the term of this Agreement remain a corporation duly organized, validly existing and
in good standing under the laws of its jurisdiction of organization. 
 3.2 MANUFACTURER will comply, in all material respects, with all laws and
regulations applicable to it, including those applicable while it is a foreign manufacturer which has no location in Japan but has a special approval (Gaikoku Tokurei Shonin Shutoku Sha) issued by MHLW under PAL. 

4. MAH’s Activities and Responsibilities 
 4.1 MAH
hereby agrees to provide all services listed in Appendix A, which is attached hereto and incorporated herein by reference. MAH will perform those services in accordance with this Agreement (including Appendix A) and the Quality Agreement, as
referred in Section 5. 

  
 3 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 4.2 MAH hereby agrees and undertakes diligently to inform the Japanese Authorities that it has been
designated by the MANUFACTURER to be its DMAH, which is established in Japan and in accordance with PAL. 
 4.3 MAH agrees that all Pre-market Approvals or
Pre-market Approval Certifications will be issued in the name of MANUFACTURER and not MAH. 
 5. Quality Agreement 

5.1 MAH and MANUFACTURER will enter into a Quality Agreement for each of MANUFACTURER’s manufacturing facilities (excluding suppliers of components or raw
materials for PRODUCTS)to assist MAH in meeting its obligations as DMAH to maintain proper controls of PRODUCTS as required by PAL. Subject to the terms and conditions of the Quality Agreement and this Agreement, MAH will have the right to represent
the MANUFACTURER as its DMAH before the Japanese Authorities regarding the PRODUCTS. The MAH will forthwith inform the MANUFACTURER of the imminence or initiation of any action by Japanese Authorities and will monitor such action on behalf of the
MANUFACTURER as its DMAH as required by applicable Japanese law. The MAH will also, pursuant to disclosures by MANUFACTURER in accordance with its respective legal obligations, report to the Japanese Authorities, reportable events of which it is
informed by MANUFACTURER related to the PRODUCTS. MANUFACTURER will provide information reasonably required by MAH. Reportable events and corrective actions will be reported in accordance with the Japanese reporting and time frame requirements. MAH
will participate in reportable event assessments with the Japanese Authorities from time to time. MAH will, as MANUFACTURER’s DMAH for the PRODUCTS, present the perspective of MANUFACTURER to the Japanese Authorities in advance to alleviate the
risks of field safety corrective action (or recall) or sales restrictions. If MANUFACTURER makes MAH aware of an anticipated risk of reportable event(s), MAH will, subject to the conditions in Appendix A and this Agreement, inform the Japanese
Authorities, and MANUFACTURER hereby grants MAH authorization, within the time frame established by law, upon prior or simultaneous, or retroactive notice (if an action plan is reasonably inevitable under any applicable Law, as defined below) to
propose an action plan to address the risk level. 

  
 4 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 5.2 The MANUFACTURER, subject to the terms and conditions of the Quality Agreement, understands and agrees
that the MAH may control and improve, if necessary, the procedures established between MANUFACTURER and its distributors, if any, in Japan (hereinafter referred as “DISTRIBUTORS”) for handling reportable events reporting. In case of
serious reportable events or risks thereof known first by the DISTRIBUTOR, MAH will be immediately informed and will determine what action should be taken. MAH will be notified by MANUFACTURER and/or DISTRIBUTOR of each reportable event and will be
provided a copy of the answer (Corrective Action) sent by MANUFACTURER to the DISTRIBUTOR. MAH will keep these records available for inspection by Japanese Authorities. 

5.3 MAH will hold, and make available to Japanese Authorities upon lawful request, an updated copy of the Shonin document as set forth in the Quality
Agreement. MAH will promptly request MANUFACTURER to provide any additional information requested by Japanese Authorities. However, MAH will not divulge confidential information concerning MANUFACTURER’s business except as may be necessary to
carry out its activities under this Agreement and Quality Agreement, and in accordance with any applicable law, directive or regulation (hereafter, “Law”), in which case it will advise MANUFACTURER of the details of the disclosure. This
confidentiality obligation will survive the termination of this Agreement and the Quality Agreement unless MANUFACTURER relieves MAH of its confidentiality obligations. 

5.4 MANUFACTURER and MAH agree to perform their respective obligations hereunder complying with PAL. Notwithstanding the foregoing, nothing contained in this
Agreement shall be interpreted to imply that the MAH is assuming responsibility for compliance of the PRODUCTS with any applicable Law (including PAL). MAH ASSUMES NO RESPONSIBILITY, AND EXPRESSLY DISCLAIMS, ANY LIABILITY HEREUNDER OR IMPLIED BY LAW
FOR THE FITNESS, SUITABILITY, MARKETABILITY, SAFETY, FUNCTIONALITY, OR LEGAL COMPLIANCE OF ANY PRODUCT. 

  
 5 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 5.5 In performing services under this Agreement, the MAH shall create, complete, approve, sign, and/or file
all documents, statements, certificates, submissions, evidence and application forms which acting reasonably it considers desirable in connection with meeting its obligations as MANUFACTURER’s DMAH under the PAL for PRODUCTS and shall perform
its obligations under this Agreement using all reasonable skill and care. 
 5.6 MAH shall keep MANUFACTURER regularly and timely informed as to all
material aspects of its activities as DMAH in relation to the PRODUCTS and interactions with the Japanese Authorities on any matter concerning the PRODUCTS or MANUFACTURER. MAH shall answer in timely manner all reasonable questions and provide all
reasonable information requested by MANUFACTURER in relation thereto. 
 5.7 Notwithstanding any other provision of this Agreement, MAH shall endeavor to
obtain written approval of MANUFACTURER prior to making any filing or otherwise communicating with the Japanese Authorities with respect to the PRODUCTS or MANUFACTURER, but MAH shall be excused from any obligation to initiate prior contact with
MANUFACTURER or receive prior approval from MANUFACTURER when (i) it is reasonably inevitable that the filing or communication will have to be made or (ii) MAH’s role under the PAL is inconsistent with giving prior notice or seeking
prior approval. 
 5.8 MAH shall defend, indemnify and keep indemnified MANUFACTURER, together with its officers, directors, employees and consultants, from
and against all losses, damages, liabilities, claims, costs and expenses (including, without limitation, properly incurred legal costs and other adviser’s fees) that result from (i) any grossly negligent or wilfully wrongful acts or
omissions of MAH and/or its officers, directors, employees, agents, advisers or contractors in relation to its performance of its obligations under this Agreement or (ii) any material breach of any representation and warranty made by MAH
(collectively referred to as “Covered Matters”). Notwithstanding any provision to the contrary, in any event MAH’s liability to MANUFACTURER under this Agreement will not exceed the total fees paid to MAH during the past fifteen
months before the date of the actions giving rise to the liability. This Section 5.8 will survive the termination of this Agreement. 
 5.9 Each party
will not be liable to the other for special, incidental, consequential, or punitive damages. This Section 5.9 will survive the termination of this Agreement. 

5.10 If any provision of this Agreement and Quality Agreement conflicts, the provision in Quality Agreement will prevail. This Section 5.10 will survive
the termination of this Agreement. 

  
 6 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 6. Obligations of MANUFACTURER 

6.1 MANUFACTURER will comply with all requests for information from MAH that are necessary to comply with any applicable Japanese Law concerning PRODUCTS and
any other applicable Law relating to the manufacture of the PRODUCTS. 
 6.2 MANUFACTURER will immediately inform MAH of all reportable events, and known
risks of reportable events, and will transmit to MAH all information which is reasonably considered necessary to protect patients and users in relation to the PRODUCTS. MANUFACTURER and MAH will promptly confer with a view to achieving consensus as
to the accurate position statement and answers to be given Japanese Authorities regarding such matters. In addition, MANUFACTURER will report to MAH in writing by January 31 of each year during the term of this Agreement whether or not
reportable events have occurred during the preceding year. This reporting obligation will survive the termination of this Agreement for as long as any PRODUCT bearing MAH’s name on the label is available to the market, or as otherwise required
by Law. 
 6.3 MANUFACTURER will inform MAH by written notice of any change which should be recorded in the Shonin Document and the Quality Agreement

 6.4 MANUFACTURER will from time to time verify with the MAH whether new claims printed on the labels, packaging, manuals and other documents or materials
will change the regulatory status (e.g.: class) of the PRODUCTS as set forth in the Quality Agreement, and are in compliance with applicable Law, especially Japanese regulations. 

  
 7 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 6.5 MANUFACTURER will deliver to MAH the list of DISTRIBUTORS established in Japan, together with their
addresses, and will provide written notice of any change in the identity or address of DISTRIBUTORS. MANUFACTURER will include the following clause in all PRODUCT distribution agreements with DISTRIBUTORS: 

Customer Complaints: Inquiries. DISTRIBUTOR may be contacted by the customer and/or end-users with respect to complaints or alleged
non-conformance of the PRODUCTS. DISTRIBUTOR will inform the MAH directly of any complaint or alleged non-conformance that may raise matters of vigilance and post-market surveillance (early warning) in accordance with PAL. DISTRIBUTOR shall
contemporaneously provide MANUFACTURER with a copy of all its communications with the MAH. DISTRIBUTOR will provide technical support on the usage of PRODUCTS to the customers based on information supplied by MAH or MANUFACTURER. DISTRIBUTOR
reporting should follow the current Japanese guidelines. 
 Contact Details: 

DESIGNATED MARKETING AUTHORIZATION HOLDER in Japan 

RIKEN GENESIS CO., LTD. 
 1-5-1
Taito, Taito-ku, 
 Tokyo 110-8560 JAPAN 

Tel: +81.3.3839.8043 
 6.6 MANUFACTURER will hold
appropriate training courses concerning the reportable events reporting system for the staff of authorized DISTRIBUTORs in Japan who work with the PRODUCTS. Subject to Appendix A, MAH is available during its business hours on its business days by
phone to give advice regarding the procedure for handling problems or reportable events. MAH may provide the on-site training activity for the DISTRIBUTORS on behalf of MANUFACTURER, subject to separate agreement on compensation for travel and other
actually incurred expenses and fees. All reimbursable expenses and fees will be determined by the parties upon mutual consultation. 

  
 8 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 6.7 MANUFACTURER is responsible for taking appropriate measures to ensure: 

 

	 	•	 	backward traceability to MANUFACTURER and MAH (name and address of the MAH shall be printed on PRODUCT packaging for PRODUCTS shipped to Japan); 

 

	 	•	 	reasonable PRODUCT traceability to users to minimize the risks in case of recall; 

  

	 	•	 	labeling requirements are met; 

  

	 	•	 	language requirements according to national legislation are met; and, 

  

	 	•	 	compliance with any other responsibilities, liabilities, and obligations as put forth in Japanese regulations for manufacturers and any other laws, statutes, directives and regulations promulgated by any Japanese
Authorities that may apply to the manufacture and distribution of PRODUCTS. 

 This Section 6.7 specifically survives the termination of
this Agreement and all responsibilities, liabilities, and obligations will extend to MANUFACTURER’s successors and assigns for at least as long as PRODUCTS with MAH’s name on the label are on the market or as required by applicable Law.

 6.8 MANUFACTURER will timely inform MAH in writing of any clinical investigation performed with PRODUCTS in Japan. Subject to Appendix A, the MAH will
keep the written report with data collected during such clinical investigations until the day the disposal of such written report and data is directed or permitted by the Japanese Authorities or under applicable Japanese law. 

6.9 MANUFACTURER will, during the term of this Agreement, extend and maintain liability insurance to MAH by providing a Vendors Coverage endorsement to
MANUFACTURER’S liability insurance policy naming MAH as additional insured. However, such insurance need not insure or protect MAH from liability resulting from MAH’s (i) grossly negligent or wrongful acts or omissions,
(ii) unauthorized activities, or (iii) material breaches of this Agreement or the Quality Agreement. Such liability insurance will cover bodily injury, property damage and related financial loss suffered by user(s) of PRODUCT(s), and
expenses for defense of any claim, for 

  
 9 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
not less than one (1) million U.S. dollars, without any financial involvement (deductible) on the part of MAH. MANUFACTURER will provide the MAH a valid latest copy of the liability
insurance policy in a timely manner. 
 6.10 If any claim (including without limitation any claim of negligence or intellectual property infringement) is
made against MAH by a third party, including any Japanese Authorities, as a result of any alleged action or omission or any alleged violation of Law on the part of MANUFACTURER (including its affiliates and agents), or any injury or damages
allegedly incurred by any third-party as a result of any PRODUCT manufactured by MANUFACTURER and sold in Japan, MANUFACTURER will promptly indemnify, hold harmless and defend (by competent counsel) MAH from and against all actions, proceedings,
damages, losses, liabilities, expenses (including reasonable attorneys’ fees) arising from or in connection with such claim (a “Claim”), unless the Claim arises solely from the alleged gross negligence or willful misconduct of MAH.
Such indemnity by MANUFACTURER will include Claims by third parties resulting from or alleged in connection with any PRODUCT manufactured, sold or distributed by MANUFACTURER, including without limitation any alleged infringement of the intellectual
property rights of a third party. 
 Either party who becomes aware of such a Claim will promptly notify the other of the assertion or threat of such a
Claim. MAH will not settle a Claim without the written consent of MANUFACTURER as to which MANUFACTURER has timely tendered a defense. The parties will cooperate fully in the defense of such Claim, provided that MAH will not be required to
(i) expend funds in defense or settlement of same, or (ii) consent to any settlement of a Claim that imposes any restriction on its lawful activities or imposes any financial obligation upon it. MAH may, at its own expense, hire
independent counsel to advise it in connection with the defense of any indemnified claim as to which MAH is providing a defense. In the event MANUFACTURER fails to provide a defense that is required hereunder, MAH may hire independent counsel to
represent it and in that event MANUFACTURER will pay the retainer requirement of MAH’s independent counsel and will promptly reimburse MAH for any additional legal fees and related expenses incurred in connection with its defense. Any
applicable insurance maintained by MANUFACTURER will, to the extent payment or defense is provided thereunder (but only to such extent), take precedence over this indemnity. This Section will survive the expiration or termination of this Agreement.

  
 10 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 6.11 MAH’s liability hereunder to MANUFACTURER will not exceed the total fees paid to MAH during the
past fifteen months before the date of the actions giving rise to the liability. MAH will not be liable to the other for special, incidental, consequential, or punitive damages. This Section 6.11 will survive the termination of this Agreement.

 7. Fees, Payments and Travel Expenses 
 7.1 Subject
to the next sentence, MAH may adjust the basic fees in the Service Package (see Appendix A) with a ninety (90) days prior notice in writing to MANUFACTURER but not more frequently than once in any twelve (12) month period and not prior to
July 1, 2012. Additional fees may, however, be charged upon MANUFACTURER’s addition of PRODUCTS or MANUFACTURER’s allocation of additional duties to MAH and/or services currently not listed in Appendix A. 

7.2 MANUFACTURER will pay MAH by bank transfer a monthly fee in accordance with the provisions of Appendix A. 

7.3 In case of serious PRODUCT reportable event(s) posing a risk of PRODUCT withdrawal from the Japanese market if MANUFACTURER requests MAH to travel, or if
MAH is required to travel by Japanese Authorities or its reasonable responsibility as DMAH, then MAH may charge such travel expenses to MANUFACTURER, after prior written approval by MANUFACTURER. 

8, Confidential Information 
 8.1 The terms and conditions
of this Agreement shall be treated as confidential information of each party. 

  
 11 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 8.2 All information and documentation provided by either party to the other party during the term of this
Agreement, including without limitation all information and documentation provided pursuant to provisions of the Quality Agreement, shall be confidential information of the disclosing party. 

8.3 Except as expressly provided in this Section 8, the receiving party shall: 
  

	 	(a)	not disclose any confidential information of the other party to any person other than any of its officers, directors, employees, agents, advisers or contractors who need to know such information in order to discharge
his duties; 

  

	 	(b)	not use any confidential information of the other party other than for the purposes of this Agreement; and 

  

	 	(c)	procure that any person to whom any confidential information of the other party is disclosed by it in accordance with subsection 8.3(a) above complies with the restrictions contained in this Section 8 as if such
person were party to this Agreement. 

 8.4 The MAH may disclose MANUFACTURER’s confidential information to the Japanese Authorities, but
only to the extent required by Law or ordered by the Japanese Authorities. The required disclosure of any information or documentation to the Japanese Authorities shall not relieve the MAH of its obligations to treat MANUFACTURER’s confidential
information in accordance with Section 8.3 hereof for all other purposes and vis-a-vis all other persons. 
 8.5 Notwithstanding the provisions of
Section 8.3, but subject to Section 8.9, either party may disclose confidential information of the other: 
  

	 	(a)	if and to the extent required by law or for the purpose of any judicial proceedings; 

  

	 	(b)	if and to the extent required by any securities exchange or regulatory or governmental body to which the party is subject or submits (wherever situated); 

 

	 	(c)	if and to the extent the information has come into the public domain through no fault of the disclosed party; 

  

	 	(d)	if such confidential information was already known by the receiving party before disclosure; 

  
 12 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	(e)	if it is independently developed by the receiving party without access to the disclosing party’s confidential information 

to its employees, directors, professional advisers, consultants, subcontractors, auditors and financial advisors (provided the receiving party
makes such disclosure on a confidential basis); 
  

	 	(g)	if and to the extent the receiving party has been given prior written consent to the disclosure by the disclosing party; or 

  

	 	(h)	that has been disclosed to the receiving party by a third party without any breach of confidence by such third party. 

8.6 Each party shall promptly inform the other party if it becomes aware of any unauthorized use of the other party’s confidential information by any
person and shall give the other party all reasonable assistance in connection with any negotiations, disputes, actions, claims or proceedings to which the other party may be a party. 

8.7 The parties agree that damages would not be a sufficient remedy for any breach of the terms of this Section 8 and that as a result the non-breaching
party shall be entitled to injunctive or other equitable relief in respect of any breach or reasonably anticipated breach and the breaching party shall not object to such remedy. 

8.8 Each party shall maintain and monitor reasonable systems and arrangements (including computer security systems) intended to ensure that the other
party’s confidential information is at all times kept secret and secure from being released to any third party not entitled to have access to the same and separate from any other information provided by it to or received from any third party
for or from whom it provides or receives services. 
 8.9 If either party is obliged to disclose any confidential information pursuant to Sections 8.5(a) or
8.5(b), it shall to the extent permitted: 
  

	 	(a)	give notice of such obligation to the other party; 

  

	 	(b)	use reasonable endeavors to resist such obligation, to the extent it is reasonable so to resist in the circumstances; 

  

	 	(c)	ensure that only information required to be disclosed is disclosed (including redacting any provisions that may be redacted); and 

  

	 	(d)	co-operate with, and keep informed, the other party in relation thereto (including providing reasonable assistance with any steps taken by the other party to resist or challenge the imposition of such obligation).

 8.10 All of the provisions of this Section 8 shall survive any termination of this Agreement for five (5) years from the date of
such termination. 

  
 13 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 9. Duration of Agreement, Termination 

9.1 This Agreement takes effect on the Effective Date set forth above and will automatically renew on each one (1) year-anniversary unless written notice
is given by either party not less than ninety (90) days prior to the such anniversary. In the event such notice is given, the Agreement will expire on the next anniversary of the Effective Date. 

9.2 This Agreement may be terminated immediately for good cause by either party upon written notice. For purposes of this Agreement, good cause will be deemed
to be one or more of the following: 
  

	 	•	 	the other party fails to cure a material breach of this Agreement within thirty (30) days after written notice reasonably specifying the breach; 

 

	 	•	 	the other party ceases to conduct business in the normal course; becomes insolvent; makes a general assignment for the benefit of creditors; suffers or permits the appointment of a receiver, trustee, or similar officer
for its business or assets; engages in fraudulent transfers; or becomes the subject of a petition filed under the United States Bankruptcy Code or any analogous state statute relating to solvency or the protection of creditor rights that is not
dismissed within 30 days. 

 9.3 On expiration or earlier termination of this Agreement, the MAH shall immediately cease to act and to purport
to act as MANUFACTURER’s DMAH except to the extent and for any period that MAH is required to act as MANUFACTURER’s DMAH by Law. 
 9.4 The
Quality Agreement will be co-terminus with this Agreement, except to the extent and for any period that MAH is required to act as MANUFACTURER’s DMAH by Law, and no further notice shall be required to effect a termination of that Agreement.

  
 14 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 9.5 On expiration or earlier termination of this Agreement, the MAH shall transfer to MANUFACTURER as soon as
reasonably practicable all documents and other materials connected with or relating to the PRODUCTS or regulatory authority for marketing the PRODUCTS which are within MAH’s possession or control. Without limiting the generality of the
foregoing, MAH will return to MANUFACTURER, at MANUFACTURER’S expense, all advertising and other materials that are the property of MANUFACTURER, including those concerning the PRODUCTS, that may be in MAH’s possession, excluding documents
required to be maintained by MAH pursuant to Law. MAH will not assert any retention or lien rights to MANUFACTURER’s materials as a consequence of any claims against MANUFACTURER. If the MAH is not permitted by Law to transfer all documents to
MANUFACTURER, it shall at a minimum provide copies of all relevant documents to MANUFACTURER at MANUFACTURER’s cost, unless prohibited by Law from doing so. The MAH shall transfer such documents in an orderly fashion (including digital format
as PDF or Word documents) and provide such additional information as is reasonably necessary to allow MANUFACTURER or its representatives to continue to market the PRODUCTS in Japan. This Section 9.5 will survive the termination of this
Agreement. 
 9.6 Obligations of the parties regarding compliance with applicable compulsory provisions of Law, including retention of records, will survive
the termination of this Agreement for as long as any PRODUCT with MAH’s name on the label is available to the market or as otherwise required by any applicable Law. If there is any conflict between the provisions of this Agreement or of the
Quality Agreement and any Law, the latter shall prevail. 
 10. Intellectual Property Rights 

MAH will not at any time assert any right to any Intellectual Property Rights associated with or related to any of the PRODUCTS. This Section 10 will
survive the termination of this Agreement. 

  
 15 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 11. Timeliness of Claims; Non-Waiver 

11.1 Unless a longer period is mandated by applicable Law, notice of all claims, except for indemnification claims under Sections 5.8 or 6.10, made by either
party against the other relating to this Agreement must be specified in writing by the claimant to the other party no later than twelve (12) months after expiration or earlier termination of this Agreement (or such later period as is 12 months
after each occurrence of any event provided in any provision of this Agreement which survives the date of expiration), or they will be forfeited and barred. 

11.2 The waiver of, or failure to enforce, a right granted by this Agreement will not be deemed a waiver of such right in any other circumstance. 

11.3 All of the provisions of Section 11 shall survive the termination of this Agreement. 

12. General Provisions 
 12.1 Nothing in this Agreement is
intended to or shall operate to create a partnership between MANUFACTURER and the MAH or, other than as specifically set forth in this Agreement, to authorise either party to act as agent for the other, and neither Party shall have authority to act
in the name or on behalf of or otherwise to bind the other in any way (including but not limited to the making of any representation or warranty, the assumption of any obligation or liability and the exercise of any right or power). 

12.2 This Agreement merges and supersedes any prior or contemporaneous written or oral agreements between the parties with respect to the subject matter
hereof, except for the Quality Agreement referenced herein and the Mutual Non Disclosure Agreement between the parties dated 26th April 2010, each of which shall remain in full force and effect. This Agreement may be modified or amended only by
the written instrument signed by an authorized representative of each party hereto. No waiver shall be effective unless it is set forth in a written instrument executed by the party hereto waiving a breach or default hereunder. No consent to or
waiver of any breach or default in the performance of any obligation hereunder shall be deemed or construed to be a consent to or waiver of any other breach or default in the performance of the same or any other obligation hereunder. Failure on the
part of any party hereto to complain of 

  
 16 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 
any act or failure to act of any other party hereto or to declare any other party hereto in default of any obligation hereunder, irrespective of how long such failure continues, shall not
constitute a waiver of rights hereunder. 
 12.3 Either party may assign this Agreement in connection with a merger, consolidation, or a sale or transfer of
all or substantially all of the assets to which this Agreement relates. This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the respective parties. In the event of assignment permitted by this
Agreement, the assigning party will give prompt written notice to the other. MANUFACTURER should verify in advance with the MAH that any proposed assignment will not result in re-registration of PRODUCTS with the Japanese Authorities. Any assignment
of this Agreement effected in accordance with the provisions hereof shall also serve to assign the Quality Agreement. 
 12.4 If a tribunal of competent
jurisdiction should find any provision of this Agreement or of the Quality Agreement invalid or unenforceable, such provision will be deemed reformed to the minimal extent necessary to preserve its intent and render it valid and enforceable, and if
reformation is not practicable, the invalid provision will be deemed severable and the balance of the Agreement or of the Quality Agreement, as the case may be, will remain enforceable to the full extent permitted by Law. 

12.5 This Agreement and the Quality Agreement will be governed by and construed in accordance with the laws of Japan. All disputes or controversies arising
between the parties out of or in relation to this Agreement or the Quality Agreement shall be finally settled by arbitration in Tokyo, Japan in accordance with the Commercial Arbitration Rules of The Japan Commercial Arbitration Association with all
proceedings conducted and all submissions made in the English language. The award rendered by the arbitrator shall be final and binding upon the parties hereto. 

12.6 All obligations herein, including those which survive the termination of this Agreement, will be binding upon the successors and permitted assigns of
each party. 

  
 17 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 12.7 All capitalized terms used in this Agreement or in the Quality Agreement that are not expressly defined
herein will have the meanings commonly associated with such terms in the medical device industry. Headings are solely for convenience and will not govern interpretation of this Agreement or to the Quality Agreement. 

12.8 The principle that contracts will be construed against the draftsman will not apply to this Agreement or the Quality Agreement. 

12.9 The official text of this Agreement and of the Quality Agreement shall be in the English language, and such English text shall be controlling in all
respects, notwithstanding any translation hereof required under the laws and regulations of Japan. Both MANUFACTURER and the MAH undertake to use the English language in respect of all documents and communications related to this Agreement or the
Quality Agreement or contemplated hereby, except where another language must be used under the Law. In any such case, MANUFACTURER may request an English translation from MAH and such English translation will be supplied to MANUFACTURER by the MAH
if the parties agree the charge and other conditions upon mutual consultation. MANUFACTURER hereby acknowledges that such English translation is made only for MANUFACTURER’s reference and shall not be deemed as any official or certified
documents. 
 12.10 Notices permitted or required by this Agreement or the Quality Agreement will be in writing, addressed to a principal at the other
party, and effective when (i) hand delivered, including by reputable courier service, (ii) delivered by facsimile, provided that the sender retains proof of successful time-dated transmission of such electronic transmission, and provided
further that such electronic transmissions received after 5 p.m. by the recipient will be deemed effective on the next business day, and (iii) mailed by certified or registered mail, postage prepaid, return receipt requested, properly addressed
to the recipient as set forth below, provided that delivery will be deemed to have occurred six (6) days after the date of the initial post-mark. 

  
 18 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

			
	If to MANUFACTURER:	  	Oxford Immunotec Ltd.
		  	94C Milton Park
		  	Abingdon, Oxfordshire OX14 4RY
		  	England
		  	Facsimile: +44 1235 442781
		
		  	Attention: Chief Scientific Officer

  

			
	If to the MAH	  	RIKEN GENESIS CO., LTD.,
		  	 3F Tappan Building East, 1-5-1 Taito,
 Taito-ku,
Tokyo 110-8560 JAPAN

		  	Facsimile: +81 3 3839 8046
		
		  	Attention: Chief Executive Officer

 Communications between the parties with respect to the subject matter of this Agreement or the Quality Agreement may be
effected through email and between representatives of the parties who are not officers of the party. Email may also be used to communicate any approval that may be required by this Agreement or the Quality Agreement (e.g., the approval described in
Article 5.7 hereof), but no approval transmitted via email will be binding on a party unless and until (i) it is sent by an officer of the party or another representative of the party specifically authorised in writing to issue approvals under
this Agreement and (ii) its receipt by the receiving party is confirmed in writing (which may be effected via email). 
 12.11 All Appendixes attached
hereto are a part of this Agreement. In the event of any inconsistency between any provision in any Appendix and the body of this Agreement, the body of this Agreement will control. 

12.12 This Agreement and the Quality Agreement may be executed in one or more counterparts, each of which constitutes an original but all of which together
constitute one document, and by facsimile transmission or by portable document format (pdf), which facsimile and pdf signatures shall be considered original executed counterparts. No counterpart shall be effective until each party has executed at
least one counterpart. 

  
 19 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 12.13 All of the provisions of Section 12 shall survive the termination of this Agreement and the
termination of the Quality Agreement. 
  

									
	RIKEN GENESIS CO., LTD.	 		 	Oxford Immunotec Limited
					
	By:	 	 /s/ Yusuke Tsukahara
	 		 	By:	 	 /s/ Dr. Peter Wrighton-Smith

					
	Name:	 	 Yusuke Tsukahara
	 		 	Name:	 	 Dr. Peter Wrighton-Smith

					
	Title:	 	 Chief Executive Officer
	 		 	Title:	 	 Chief Executive Officer

					
	Date:	 	 29 July 2011
	 		 	Date:	 	 1st August 2011

  

  
 20 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 APPENDIX A 

DMAH Service Package for In-Vitro Diagnostics 
  

	 	•	 	We (MAH) support marketing in Japan for the PRODUCTS placed on the market by the foreign manufacturer. 

  

	 	•	 	We must act as the foreign manufacturer’s contact point for all Japanese Authorities. 

  

	 	•	 	We oversee the GQP and will be in charge of monitoring the shipping and receiving methods of the foreign manufacturer. 

  

	 	•	 	We are responsible for notifying the PMDA of any manufacturing or in-process control changes. 

  

	 	•	 	We communicate with your DISTRIBUTOR and create the Import Procedure for your DISTRIBUTOR. 

  

	 	•	 	We communicate with your packaging manufacturer to develop the Quality Agreement and assist in preparation of the Manufacturing Standard (Seihinhvojunsho) for labeling and warehousing as applicable.

  

	 	•	 	We are responsible for establishing and ensuring the release criteria and Quality Standard (Hinshitsuhyojunsyo) for each PRODUCT. 

 

	 	•	 	We prepare and submit the Import Submission for each PRODUCT family for customs clearance. 

  

	 	•	 	We register JAN code to MEDIS for each item of the PRODUCTS. 

 We are responsible for
handling all necessary communication between foreign manufacturer and MHLW in the case of a PRODUCT recall. 
  

	 	•	 	We protect the confidentiality of your documentation. The Japanese Authorities are the only entities to whom we will show the documents, and only upon their request. 

  
 21 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	•	 	We obtain your PAL certificates and other documentation for each PRODUCT from the Japanese Authorities and forward them to you. We will ensure that all certificates and approvals will be issued in your
(MANUFACTURER’S) name. 

  

	 	•	 	We have right to conduct audits of your facilities. The MAH must be able to show their audit records of the foreign manufacturer which has no location in Japan to Japanese Authorities upon request. If your company faces
a serious or many reportable events, this will be expected. 

  
 22 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 Fee Structure 
  

	 	•	 	One time initiation fee of [***] upon signing of this Agreement. This includes the fee for review of IVD documentation, labeling, and developing the required Quality Standard (Hinshitsuhyojunsyo) and Import Submission,
Quality Agreement, JAN Code registration. An additional one-time [***] fee per a PRODUCT family is required for an additional PRODUCT family. This also includes the review of IVD documentation, labeling, and developing the required Quality Standard
(Hinshitsuhyojunsyo) and Import Submission. 

 DMAH Retainer and Handling Fee: 

We charge a monthly retainer handling fee and commission per commercial invoice at custom clearance for PRODUCTS listed in APPENDIX B (collectively the
“Monthly Fee”) 
 We offer the following two Monthly Fee options. 

OPTION 1: 
 [***] per month plus [***] commission applied to
each commercial invoice for a PRODUCT listed in APPENDIX B, invoiced monthly. 
 OPTION 2: 

[***] per month plus [***] commission applied to each commercial invoice for a PRODUCT listed in APPENDIX B, invoiced monthly. 

Note: 
  

	 	•	 	Once you have reached [***] in total fees paid to MAH for the current calendar year, MAH will waive the Monthly Fee going forward for the remainder of the calendar year (except as set forth in the next succeeding bullet
point). 

  
 23 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	•	 	However, if the total invoiced amount for the year cleared through customs reaches [***], MAH will charge a [***] commission on the invoiced amount in excess of the [***] in addition to the already charged [***].

 To set-up Import Procedure for shipping process, [***] is charged to your DISTRIBUTOR, if any. This includes necessary
communication with the DISTRIBUTOR including explanation of new import procedure. 
 If necessary, vigilance/reportable event reporting will
be charged on an hourly rate basis of [***]. 
 If an on-site audit of your facilities is required, fees will be charged at the rate of [***]
per person per day, with a fee cap of [***] (2 persons for 2 days). In addition, Manufacturer will reimburse MAH for reasonable out-of-pocket travel expenses of the auditing team, at cost (without mark-up), with all air travel in economy class and
accommodations at standard business (not luxury) hotels. MAH will endeavour to use audit personnel who are geographically proximate to the facility to be audited. In the event the on-site audit cannot be completed by two persons in two days (or by
one person in four days), the parties agree to discuss appropriate adjustments to the fee cap. 
  

	 	•	 	Travel expenses where applicable are charged at cost. 

  

	 	•	 	Manufacturer is responsible for payment of all fees related to the Product registration charged by the PMDA or Registration Certification Body. 

 

	 	•	 	The amount of fees for custom clearances including consumption taxes to be paid at customs clearance which must be paid to MAH before customs clearance can occur. We will invoice the amount of fees to your DISTRIBUTOR
as a substantial importer and not release PRODUCT to your DISTRIBUTOR until paid. 

  

	 	•	 	If RIKEN GENESIS is assuming the DMAH role for any Product from the MANUFACTURER’s existing MAH/DMAH, RIKEN GENESIS must gather the following information and perform the additional actions itemized below. Our
assistance with the following activities will be billed at a fee of [***] per hour, plus travel time and travel expenses, which are invoiced at cost: 

  

	 	•	 	Obtain the GQP and GVP, including quality control records, release judgment records and adverse event/field corrective action records, complaint data, et al. 

  
 24 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

	 	•	 	Succeed original copy of the Pre-Market Approval/Certification (PMA/PMC) and copy of the application of the Pre-Market Approval/Certification (PMA/PMC) 

Succeed copy of package insert, instruction for use/operation manual and labeling 

 

	 	•	 	Prepare and submit DMAH Change Notification 

 Notes: 

 

	 	•	 	In Japan, class I IVDs are not required to go through the Pre-market Approval or Pre-market Certification process. Instead, registration is executed by the Pre-market Submission process with no assessment by the PMDA or
a registered Certification Body as is required with a Pre-market Approval or Pre-market Certification. 

  

	 	•	 	While the Foreign Special Approval System under the PAL is not applicable for PRODUCTS that fall under the Pre-market Submission process, you can select MAH as your MAH rather than as your DMAH. 

 

	 	•	 	Manufacturer must appoint a licensed Packaging Manufacturer, Distribution Company and if necessary a Logistics Firm licensed for your specific PRODUCTS. 

In the case of a transfer of existing registered PRODUCTS from your existing MAH or DMAH, MANUFACTURER is responsible for providing all of the
documents, e.g., pre-market approval application, package insert, Quality Standard (Hinshitsuhyojunsyo) etc., needed to transfer from the existing MAH or DMAH. Any fee and/or costs for re-registration of the PRODUCTS transferred from the existing
MAH or DMAH will be charged separately. 

  
 25 

 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT
REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. 
  

 APPENDIX B 

This Appendix B may be revised and amended from time to time by mutual agreement by the parties. 

List of PRODUCTS 
 Please list the trade name of
the PRODUCT marketed in Japan and its facility. 
  

					
	 No.
	  	 Trade Name
	  	 Facility

			
		  	T-Spot ® TB test	  	

  

	 	•	 	Please list the trade name of the PRODUCT marketed in Japan and its facility. 

 MAH represents that all
PRODUCTS currently listed on Appendix B constitute only one PRODUCT family. 
  

									
	RIKEN GENESIS CO., LTD.	 		 	Oxford Immunotec Limited
					
	By:	 	 /s/ Yusuke Tsukahara
	 		 	By:	 	 /s/ Dr. Peter Wrighton-Smith

					
	Name:	 	 Yusuke Tsukahara
	 		 	Name:	 	 Dr. Peter Wrighton-Smith

					
	Title:	 	 Chief Executive Officer
	 		 	Title:	 	 Chief Executive Officer

					
	Date:	 	 29 July, 2011
	 		 	Date:	 	 1st August 2011

  
 26

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00222-of-00352.parquet"}]]